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ZUSAMMENFASSUNG 
 
Die Metastasenbildung ist das letzte, lebensgefährliche Stadium eines Tumors. 
Deswegen ist es wesentlich zu verstehen, wie dieser Prozess reguliert wird, um einen 
therapeutischen Eingriff zu ermöglichen. ASAP1 (Arf-GAP mit SH3-Domänen, Ankyrin-
repeat Proteinen and PH-Domänen) wurde während eines unvoreingenommenen 
genetischen Screenings von Genen entdeckt, die an der Metastasenbildung beteiligt 
sind. Anschließend wurde gezeigt, dass dieses Protein die Motilität und Invasivität von 
Tumorzellen fördert. In einem Pankreaskarzinom-Modell wurde durch „loss-of-
function“ und „gain-of-function“ Versuche bewiesen, dass ASAP1 eine funktionelle 
Rolle bei der Regulation der Metastasierung spielt. Die Expression von ASAP1 in 
Patienten mit kolorektalem Karzinom korreliert stark mit einer kurzfristigen 
Überlebensrate ohne Metastasenbildung und einer schlechten Prognose. Auf 
molekularer Ebene zeigten Koimmunpräzipitationsexperimente, dass ASAP1 sowohl h-
prune als auch Nm23-H1 (nicht-metastatisches Protein 23-H1) binden kann, die beide 
auch in die Regulation des metastatischen Prozesses involviert sind. Zielsetzung 
meiner Arbeit war es, durch die Verwendung der hochmetastasierenden Brustzelllinie 
MDA MB 231, die ASAP1, Nm-23H1 und h-prune endogen exprimiert, zu untersuchen, 
wie ASAP1 zur Metastasenbildung beiträgt. Dabei habe ich folgende Aspekte 
analysiert: a) den Einfluss von ASAP1 und seiner Interaktionspartner bei der 
Internalisierung von EGF; b) den Einfluss von Proteinkomplexen, die ASAP1 enthalten, 
auf die Zellmotilität; c) weitere mögliche Interaktionspartner, die die Aktivität von 
ASAP1 beeinflussen könnten. Meine Ergebnisse haben gezeigt, dass weder Nm23-H1 
noch h-prune, trotz ihrer Rolle bei der Regulation der Motilität und der 
Metastasenbildung, den Einfluss von ASAP1 auf die Zellmigration beeinflussen. 
Außerdem wirken sich diese beiden Proteine auch nicht auf die Fähigkeit von ASAP1 
aus, die Internalisierung von EGF zu regulieren. Ich habe dann meinen Schwerpunkt 
auf andere mögliche Proteine gelegt, die zur ASAP1-vermittelten Metastasenbildung 
beitragen könnten. Dafür habe ich ein Screening zur Findung potentieller 
Interaktionspartner durchgeführt, die SH3- Domänen besitzen, da die SH3-bindende 
Domäne von ASAP1 äußerst wichtig für seine motilitätsfördernde Aktivität ist. Dadurch 
habe ich SLK (Ste--20 Like Kinase) als einen neuen Interaktionspartner von ASAP1 
ermittelt und seine Effekte auf die Funktion von ASAP1 analysiert. Obwohl SLK mit 
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ASAP1 koimmunpräzipitierte und selbst in die Regulation der Zellmotilität involviert ist, 
konnte dieses Protein nicht die zellmotilitätsfördernde Aktivität von ASAP1 
beeinflussen. Insgesamt zeigen meine Ergebnisse die Rolle von ASAP1 sowohl bei der 
Begünstigung der  Zellmotilität als auch bei der Förderung der 
Rezeptorinternalisierung im Kontext von Tumorzellen. Beides sind wichtige biologische 
Prozesse, die die Metastasierung regulieren.  
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ABSTRACT 
 
 
Metastasis formation is the life-threatening end stage of cancer. It is therefore vital to 
understand how this process is regulated so that therapeutic intervention becomes 
possible. ASAP1 (Arf-GAP with SH3-domains, Ankyrin-repeats and PH-domains) was 
discovered in an unbiased genetic screen for genes that are involved in metastasis 
formation. Subsequently it was shown that this protein promotes tumor cell motility 
and invasiveness. Loss and gain of function experiments in a pancreatic carcinoma 
model demonstrated a functional role for ASAP1 in regulating metastasis. In human 
colorectal cancer patients ASAP1 expression strongly correlates with short metastasis-
free survival and poor prognosis. At the molecular level, co-immunoprecipitation 
experiments have shown that ASAP1 binds to both h-prune and Nm23-H1 (Non-
Metastatic protein 23-H1), proteins that are also involved in the metastatic process. 
Using the highly metastatic breast cell line MDA-MB-231 that endogenously expresses 
ASAP1, Nm-23H1 and h-prune, in my PhD thesis I aimed to characterize how ASAP1 
contributes to metastasis by addressing the following issues: a) the influence of ASAP1 
and its interaction partners on the internalization of EGF; b) effects of ASAP1-
containing protein complexes on cellular motility; c) further possible interaction 
partners that may modulate ASAP1 activity. My results showed that, despite their role 
in regulating motility and metastasis formation, neither Nm23-H1, nor h-prune 
influence the effects of ASAP1 on cell migration. Moreover, these two proteins also do 
not affect the ability of ASAP1 to regulate the internalization of EGF. I then focused my 
attention on other possible proteins that might contribute to ASAP1-mediated 
metastasis by screening for potential SH3 domain-bearing interaction partners, 
because the SH3 binding domain of ASAP1 is crucial for its motility-promoting activity. I 
thereby identified SLK (Ste-20 Like Kinase) as a new interaction partner of ASAP1, and 
analyzed its effects on ASAP1 function. Although SLK co-immunoprecipitated with 
ASAP1, and is itself involved in the control of cell motility, this protein did not affect the 
motility-promoting activity of ASAP1. Together, my results demonstrate the role of 
ASAP1 in promoting both cell motility and receptor internalization in the context of 
tumor cells, important biological processes that regulate metastasis formation. 
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1. INTRODUTCION 
 
1.1 Cancer 
 
1.1.1 General features 
 
The terms neoplasia, tumor and cancer all refer to a common pathological state, 
namely the aberrant growth of a mass of proliferating cells that have been 
transformed, caused by a variety of stimuli. Although many of the triggering events that 
lead to cellular transformation have been identified, including certain viral and 
bacterial infections, chemical compounds and radiation, the etiology of the majority of 
tumors is still unknown. There are, nevertheless, several proved risk factors, such as 
age, gender, life style, race and the environment. Our scarce knowledge in this 
pathology is reflected by the fact that cancer is one of the leading causes of death in 
developed countries, counting for approximately 25% of all deaths in 2008 (Jemal et 
al., 2008).  
In 2000 Hanahan and Weinberg proposed a way to characterize cancer in “six 
hallmarks of cancer”, which include the features the tumor acquires during its 
development, and distinguishes it from healthy tissues (Hanahan and Weinberg, 
2000). These are: 
♦ Sustaining proliferative signalling 
♦ Evading growth suppressors 
♦ Resisting cell death 
♦ Enabling replicative immortality 
♦ Inducing angiogenesis 
♦ Activating invasion and metastasis 
The first version of the hallmarks of cancer has now been revised to take into 
consideration that a tumor mass is not composed of just tumor cells, but is a complex 
interaction between the transformed cells and recruited cells, the primary tissue and 
the host environment (Hanahan and Weinberg, 2011). These hallmarks have been 
integrated with the concept of “enabling characteristics” that are required for tumor 
development. Two of these enabling characteristics are genomic instability and 
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mutation of cancer cells, and tumor-promoting inflammation. Some authors even 
consider inflammation as the seventh hallmark of cancer (Colotta et al., 2009). To 
complete the scenario, other factors have been included, namely two additional 
“emerging hallmarks”: reprogramming energy metabolism, and evading immune 
destruction (Figure 1). 
 
Figure	  1:	  Hallmarks	  and	  enabling	  characteristics	  of	  cancer	  development	  (adapted	  from	  Hanahan	  and	  Weinberg,	  2011).	  
  
Alterations to cellular metabolism have also been proposed as hallmark of cancer by 
Cairns, Harris and Mak (2011), who argue that the final aim of many oncogenic 
pathways is the adaptation of the tumor cell metabolism in order to sustain rapid 
growth and survival. Indeed, as early as 1930 Warburg observed that tumor cells 
undergo a glycolytic switch, and limit their metabolism to glycolysis even in the 
presence of oxygen (“aerobic glycolysis”), avoiding oxidative phosphorylation in the 
mitochondria (Warburg, 1926).  
Finally, new findings have shown the importance in tumor biology of the tumor 
microenvironment, which includes not only several cell types, but also biological 
characteristics such as pH variations and hypoxia. Tumor cells have a constant signal 
exchange with the microenvironment during development. Cancer-associated 
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fibroblasts (CAFs), pericytes, endothelial cells and bone marrow-derived cells (BMDC) 
all participate in a complex signalling environment, which changes during tumor 
progression and eventually promotes metastasis formation (Hanahan and Weinberg, 
2011). In recent years, tumor-associated macrophages (TAMs), myeloid-derived 
suppressor cells (MDSC) and mesenchymal stem cells (MSC) have often been 
correlated with tumor growth and malignant progression in a variety of studies (Joyce 
and Pollard, 2009). 
 
1.1.2 Activating invasion and metastasis 
 
1.1.2.1 General concepts 
The main threat to cancer patient survival is the development of metastatic potential 
(Talmadge and Fidler, 2010). The survival rate for cancer patients whose primary 
tumors have begun to spread drops dramatically. Metastasis is defined as the spread 
of cancer cells from the primary site to other parts of the body. It is characterized by 
several distinct steps, the first (after initial transformation and angiogenesis) being 
local invasion (Figure 2). This process includes changes in the adhesive properties of 
the cell, and the activation of proteolysis, which is necessary for the cells to create a 
protrusion (Wang et al., 2005). Here, matrix metalloproteinases (MMPs) remodel the 
surrounding matrix and allow tumor cells to cross non-permissive tissue barriers. 
Examples include MMP2, 9 and 14 (Gialeli et al., 2010). These proteins are produced 
not only by the tumor cells, but also by the surrounding fibroblasts in response to 
paracrine stimuli coming from the tumor (Murphy et al., 2008). In general, the primary 
tumor itself secretes factors that promote the migration of tumor cells in both an 
autocrine and paracrine manner. Cells from the immune system, bone marrow derived 
cells, endothelial cells and fibroblasts that infiltrate the tumor tissue produce a variety 
of factors such as EGF, HGF, TGFβ, HGF and CCL5, that activate the migration 
machinery (Christofori, 2006). 
Cancer cells that invade into the surrounding tissue can reach either blood or lymph 
vessels where they will intravasate, entering either the blood stream or the lymphatic 
circulation as circulating tumor cells (CTCs). According to the parallel progression 
model, this spreading of CTC can happen already at very early stages of tumorigenesis, 
even before the clinical appearance of the disease (Klein, 2009). Many CTCs are 
apoptotic because they have lost contact with their substrate, or die due to the shear 
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forces in the circulation (Sleeman et al., 2011). The few CTCs that survive will 
eventually arrest in capillaries and extravasate into the new tissue. There the 
disseminated tumor cells (DTCs) may start to proliferate and induce angiogenesis, in 
order to supply nutrients and oxygen to the rapidly growing mass (Talmadge and Fidler, 
2010). Every step in this process includes many rate limiting obstacles for metastasis 
formation. The process of metastasis is thus inefficient, seldom exceeding 0.01% 
(Fidler, 1970).  
 
Figure	  2:	  The	  invasion-­‐metastasis	  cascade	  (adapted	  from	  Talmadge	  and	  Fidler,	  2010)	  
 
Not all tumor cells acquire the ability to give rise to metastasis, and only those that 
have undergone “advantageous” genetic changes seem to be the ones able to locally 
invade the tissue, as described by the clonal selection model (Fidler and Kripke, 
1977). However, this model has now been re-evaluated, as genomic instability and 
epigenetic changes may be necessary but not sufficient for the development of 
metastasis. An interaction with the stroma and the stromal cells, including remodeling 
of the ECM, induction of angiogenesis, local hypoxia and inflammatory conditions, is 
essential for the further progression of the tumor (Sleeman et al., 2012).  
 
1.1.2.2 Role of the macrophages 
Not every tumor cell is able to move away from its primary site and reach the 
lymphatics or the blood stream. This may be due to the suppressive effect of the 
immune system cells present at the original location (Hayakawa and Smyth, 2006). 
However the immune system also has positive effects on tumor progression. The 
tumor-associated macrophages (TAMs) are recruited and activated from the bone 
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marrow by tumors through secretion of cytokines such as CCL-2, and can be of two 
subgroups, M1 and M2. M1 macrophages give an anti-tumoral response by secreting 
pro-inflammatory cytokines as TNFα and IL-12 (Coghlin and Murray, 2010). In contrast, 
the M2 subtype secretes IL-10, VEGF-A and TGFβ, which rather promote angiogenesis 
and exert immunosuppressive functions (Solinas et al., 2009). Moreover, 
macrophages can also secrete proteases that contribute to the extravasation process 
(Kessenbrock et al., 2010). M2 TAMs are most frequently found in later stages of 
tumor, whereas the M1 activated macrophages seem to play a role rather at the 
beginning of tumor development (Biswas et al., 2008). Another subtype of TAM has 
been recently discovered that expresses Tie-2 and promotes angiogenesis (De Palma 
et al., 2005).  
 
1.1.2.3 The epithelial-mesenchymal transition (EMT) 
Epithelial cells can to loose many of their characteristics and take on mesenchymal 
features in a complex process termed EMT. This transition results in a more motile 
phenotype and changes the adhesive properties of the cells, and has therefore been 
connected with the metastatic process (Thiery, 2002). For example, the loss of 
epithelial markers such as E-cadherin has been correlated with poor prognosis 
(Peinado et al, 2004). The EMT process has a pivotal role during embryogenesis, and 
the very same factors that regulate it in this physiological condition, like SNAI1, Slug 
and Twist, are also involved in EMT in the tumor context. In fact, changes in the 
expression of these factors due to genomic instability in tumor cells may be the 
triggering event for EMT (Thiery and Sleeman, 2006). Growth factors derived from both 
tumor and stromal cells, including TGFβ, stimulate the expression of these 
transcription regulators, which act as suppressors of the promoter for E-cadherin. This 
results in a loss of this protein and thus a loss of cell-cell interactions and a 
consequent morphological switch to a spindle-like shape (Onder et al., 2008). The loss 
of E-cadherin is accompanied by the gain of N-cadherin (“cadherin switch”), which 
confers a mesenchymal phenotype to the cells and enhances migration and invasion 
(Christofori, 2006). Furthermore, EMT is characterized by the expression of proteases 
(MMPs), and increased motility and resistance to apoptosis (Hanahan and Weinberg, 
2011), typical features of invasive cells (Figure 3).  
EMT is often found at the “invasive front” of a tumor, rather than being distributed in 
the whole mass, underlying its role in promoting metastasis formation. Indeed, EMT-
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like features have been associated with metastatic potential (Thompson and 
Newgreen, 2005). Moreover, recent findings have related the EMT with the presence 
of the the so-called cancer stem cells (CSC), a tumor cell sub-population which is 
supposed to be capable of (re-)initiating tumor growth and thus to give rise to a 
metastasis (Brabletz et al, 2005). In fact, the EMT process increases the stemness of 
the cells (Mani et al., 2008).  
EMT seems to play a role not only in the metastatic process. Cancer cells also may 
take advantage of this process to avoid oncogene-induced senescence, tumor hypoxia 
and increased apoptosis, thus giving an escape route to these hurdles (Sleeman et al., 
2012).  
 
 
Figure	  3:	  EMT.	  The	  epithelium	  is	  characterized	  by	  a	  thin	  layer	  of	  cells,	  which	  have	  a	  apical-­‐basolateral	  polarity	  and	  are	  connected	  by	  specialized	  junctions	  both	  to	  each	  others	  and	  to	  the	  basal	  lamina.	  Upon	  EMT	  the	  cells	  change	  in	  morphology,	  loose	  their	  polarity	  as	  well	  as	  their	  adhesive	  properties.	  
 
1.1.2.4 The premetastatic niche 
If a tumor cell manages to survive the harsh flow of the blood stream and extravasate, 
it still has to face a new and hostile environment that will not necessarily be 
permissive. This was already clear to Paget in 1889, when he proposed his “seed and 
soil” theory, which is still wildly accepted. He argued that the metastatic cells (the 
“seed”) will survive only if they end up in a permissive organ (the “soil”). This concept 
underscores the importance of the interactions between tumor cells and host tissue, 
although nowadays the “soil” can include concepts such as the premetastatic niche 
(Talmadge and Fidler, 2010). CTCs can reach different organs, but may be able to 
“seed” as DTCs and grow in only few of them. This happens when cancer cells arriving 
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from a primary site find a microenvironment, which is already permissive and 
supportive for their colonization. The intrinsic characteristics of the tissue or the effect 
of factors released by recruited bone marrow-derived cells may help creating the 
appropriate “soil” (Peinado et al., 2011). Kaplan and colleagues first described the 
presence of bone marrow-derived (BMD) hematopoietic progenitor cells expressing 
VEGFR1 prior the arrival of metastatic tumor cells (Kaplan et al., 2005).  There are 
other molecules that have been shown to play a role in creating an appropriate 
microenvironment that facilitates the outgrowth of a tumor. For example fibronectin, 
secreted by activated fibroblasts, is able to promote the activation of lysyl oxidase 
(LOX), which is the staring point for matrix deposition and its cross-linking (Fogelgren et 
al., 2005). Molecules involved in inflammation, such as members of the S100 family 
and of the Serum Amyloid A (SAA) acute phase proteins, also contribute to the 
formation of the niche, for example by recruiting CD11b+ myeloid cells (Lukadinin and 
Sleeman, 2012). These in turn may secrete factors such as TGFβ that inhibit natural 
killer cells, B cells and the functional maturation of dendritic cells (Yang and Moses, 
2008). In fact, it is believed that myeloid cells recruited at pre-metastatic sites create 
an “immune sanctuary” that will enable the growth and proliferation of tumor cells 
(Psaila and Lyden, 2009).  
 
1.1.2.5 Tumor dormancy  
A cancer cell that succeeds in reaching and colonizing a secondary site may lie 
dormant for months or even years before it gives rise to a detectable metastasis. 
Dormant tumor cells can be characterized by an incapability to turn on the “angiogenic 
switch”, where their proliferation rate is balanced by apoptosis (Almog, 2010). 
Alternatively, they can be in a prolonged state of G0, and thus insensitive to 
chemotherapy that targets actively cycling cells (Uhr and Pantel, 2011). The 
reactivation of these cells is due both to the influence of the microenvironment, as well 
to the genotype (e.g. loss of metastasis suppressor genes) and phenotypic 
characteristics of the dormant cells (Sleeman et al., 2012).  
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1.2 Cell motility and metastasis 
 
1.2.1 Cell motility in cancer cells 
 
An important first step in metastasis for tumor cells is often the remodelling of their 
actin cytoskeleton, detachment from the primary tissue and movement towards and 
invasion into a lymphatic or blood vessel. Similar motile properties are required during 
extravasation at distant sites. Therapeutic approaches that target cell motility have the 
potential to prevent the development of systemic metastatic disease, and thus 
significantly improve cancer treatment (Palmer et al., 2011).  
The ability of a cell to move is of fundamental importance in metastasis, as well as in a 
plethora of physiological events such as development, homeostasis, the immune 
response and bone remodelling. Therefore cell motility and migration is a tightly 
regulated process. The movement of a single cell requires the following steps: 
polarization, protrusion and adhesion, translocation of the cell body and retraction of 
the rear (Sheetz et al., 1999). An extracellular stimulus is in most cases responsible 
for polarization, namely the creation of a migrating front and a rear in the cell, which 
breaks the symmetry (Horwitz and Webb, 2003). In response to a gradient of soluble 
(chemotactic) or surface bound (hapotactic) stimulus, the cell activates asymmetrically 
its receptors on the side of the stimulus, such as members of the G-protein coupled 
receptors (GPCR) superfamily (Cotton and Claing 2009). These give rise to a cascade 
of activations of downstream effectors, such as phosphoinositide 3-kinase (PI3K), 
which induce secondary messengers like phosphoinositol-trisphosphate (PIP3), that 
rapidly accumulates at the leading edge (Kölsch et al., 2008). This asymmetric 
accumulation activates Rho family GTPases, in particular Rac and Cdc42, that 
eventually affect the de novo polymerization of actin, leading to the formation of the 
structures responsible for filopodia, lamellipodia and lamellae formation (Figure 4).  
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Figure	  4:	  	  Actin	  structures	  that	  characterize	  cell	  motility.	  
 
1.2.2 Actin structures and migration mechanism 
 
1.2.2.1 Filopodia and lamellipodia 
Filopodia act mainly as mechanosensors, exploring the surrounding environment, and 
contain long, unbranched parallel actin bundles. Lamellipodia, the structures that 
generate the traction forward movement, are thin veil-like structures. They can be 
characterized by a ruffle, which is the result of a retrograde movement of a 
lamellipodium that did not adhere. The ruffle continues to fold over backward as it 
simultaneously retracts and eventually dissipates near the cell body (Figure 5) 
(Stossel, 1993). 
 
 
 
 
 
 
 
 
 
 
Figure	  5:	  Formation	  of	  a	  ruffle	  on	  the	  leading	  edge	  of	  a	  migrating	  cell.	  
 
The polymerization of actin pushes the membrane forward, and eventually causes the 
cell to move. Mainly thanks to integrins, a new contact between the ventral stress 
fibres in the cell and the substrate is formed, the nascent adhesions that contain 
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actively polymerizing actin (Parsons et al., 2010). The nascent adhesion may mature 
by elongating and growing into focal complexes, and finally into larger structures that 
stably attach and transmit force to the extracellular matrix, the focal adhesions (FAs) 
(Oakes et al. 2012).  
 
1.2.2.2 Focal adhesions 
The FAs are multiprotein structures that form a link between the actin stress fibres in 
the cell and the extracellular matrix (ECM), providing force transmission between the 
inside and outside of the cell (Geiger et al., 2009). A FA can further mature into fibrillar 
adhesions, which are not seen in migrating cells, and are composed of large stress 
fibres, characterized by the presence of tensin (Pellegrin and Mellor, 2007).  
The assembly of a FA is a highly regulated process, in which protein recruitment occurs 
in a sequential manner (Zaidel-Bar et al., 2004), and starts with integrin clustering. 
Integrins are the “anchor” of a cell to the ECM, and are able to trigger several 
transduction events such as tyrosine phosphorylation, pH elevation, synthesis of PIP2 
following Rac1 activation and activation of the MAPK cascade (Petit and Thiery, 2000). 
The integrin cytoplasmatic tails are able to bind various components of the focal 
adhesions, such as from tensin and the focal adhesion kinase (FAK) (Miyamoto et al., 
1995). 
FAK is the most important regulator of the integrin-associated focal adhesions, 
associating with Src and controlling downstream signal transduction pathways 
(McLean et al., 2007) (Figure 6). FAK is a non-receptor tyrosine kinase that binds to 
integrin clusters, mediates outside-inside signalling, and acts as an adaptor protein for 
the creation of the FA complex. The expression of FAK has been often linked in various 
epithelial cancers with the invasive potential of the tumors (McLean et al., 2005).  FAK 
autophosphorylates in response to integrin clustering, creating a docking site for the 
SH2 domain of Src that activates FAK via phosphorylation (Schaller et al., 1994). Src is 
also responsible for the formation of podosomes, the so called “cellular feet” (Tarone 
et al., 1985).  
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Figure	  6:	  FAK	  signalling.	  FAK	  autophosphorylates	  Y397	  upon	  integrin	  clustering,	  creating	  a	  binding	  site	   for	   SRC.	   The	   interaction	   of	   FAK	   with	   SRC	   causes	   a	   conformational	   change	   of	   the	   latter,	   which	  results	  in	  its	  activation	  and	  phosphorylation	  of	  two	  tyrosine	  residues	  on	  the	  kinase	  domain	  of	  FAK	  that	  activate	  it	  (adapted	  from	  McLean	  et	  al.,	  2005).	  
 
1.2.2.3 Podosomes and invadopodia 
These ring-shaped adhesions share many components with the FAs, including talin, 
vinculin and paxillin, but the Wiskott Aldrich Syndrome protein (WASP) is unique to 
podosomes. The tyrosine kinase substrate with five SH3 domains (Tks5), another 
protein found in podosomes, is found also in the invadopodia, a structure related to 
podosomes that is described below. Another difference to the FAs is the presence of 
proteins that regulate the polymerization of actin (gelsolin, the Arp2/3 complex and 
fimbrin). Podosomes are observed in monocyte-derived cells such as osteolclasts and 
macrophages, and have a similar adhesive function as focal adhesions (Buccione et 
al., 2004), although podosomes also have a role in cell invasion. The secretion of 
matrix metalloproteinases (MMP) enables the cell to degrade the ECM and promotes 
diapedesis (Calle et al., 2006), migration (Rottiers et al., 2009) and tissue infiltration 
(Cougoule et al., 2010). 
Invadopodia are closely related to podosomes, with which they share adhesive 
properties and the ability to degrade the ECM. Nomenclature of these two structures is 
still under debate, but it is generally accepted that invadopodia are found only in 
transformed and tumor cells (Murphy and Courtneige, 2011). Compared to 
podosomes, invadopodia are less frequent in the cell, and they also have a slower 
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turnover (Buccione et al., 2004). Upon outside-inside signalling from ECM-integrins or 
growth factor-receptor tyrosine kinase interactions (e.g. EGF, PDGF and TGFβ) there is 
activation of various signalling pathways, mainly involving Src and PKCµ (Bowden et 
al., 1999), and a subsequent recruitment and activation of protein components of the 
actin regulation machinery (Figure 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure	  7:	  The	  signalling	  network	   involved	   in	   the	   invadopodium	  formation.	  Black	  dots:	   tyrosine	  phosphorylation;	  solid	  lines:	  direct	  protein-­‐protein	  interaction;	  dotted	  lines:	  intermediates	  not	  known;	  Ub:	  monoubiquitination;	  dashed	  arrows:	  Src	  substrates.	  (Adapted	  from	  Stylli	  et	  al.,	  2008)	  
 
The most important components for the invadopodia are the proteins linked with actin 
polymerization (Arp2/3 complex, N-WASP and WASP interacting protein (WIP), 
cortactin), ASAP1 (Arf-GAP with SH3 domain, ANK repeat and PH domain-containing 
protein 1), the adaptor proteins paxillin and Tks5 as well as a disintegrin and 
metalloproteinases (ADAMs) and membrane type-1 matrix metalloproteinases (MT1-
MMP)  (Stylli et al., 2008).  
 
1.2.2.4 Translocation of the cell body and retraction of the rear 
To move forward the cell must translocate the body and retract the rear. The cell body 
rolls behind the lamellipodium due to a contraction of the actomyosin cytoskeleton, 
without any de novo polymerization of actin (Anderson et al., 1996). At the same time 
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myosin II decreases the tension at the leading edge, resulting in a retraction of the 
rear and a parallel extension of the front  (Jay et al., 1995; Verkhovsky et al., 1999). 
The FAs at the rear disassemble and “slide” inwards towards the front, with multiple 
proteins moving along the stress fibres, whereas integrins stay on the membrane and 
must be exchanged (Palecek et al., 1998). The protease calpain also participates in 
the retraction mechanisms by promoting the proteolysis of adhesion proteins such as 
talin 1, and integrin β3 cytoplasmatic domain (Parsons et al., 2010). 
FAK is again the main regulator of the disassembly process, as it can induce a 
decrease in local myosin contractility through downstream pathways that include ERK 
and myosin light chain kinase (MLCK) (Broussard et al., 2008). 
 
1.2.3 Different forms of migration 
 
The movement of cells can be single (amoeboid or mesenchymal) or collective (in cell 
sheets or cluster), depending on a variety of factors such as protease activity in the 
ECM, differences in cell-cell and cell-ECM adhesion, polarity of the cell and the 
rearrangement of the cytoskeleton (Yilmaz and Christofori 2010). The migration of 
cancer cells can occur with both forms, or as a combination, depending on the 
differentiation stage (Friedl and Wolf, 2003). In vivo, tumor cells also can interconvert 
between single or collective modes, as they are not mutually exclusive (Roussos et al., 
2011).  
Cells that migrate in a collective form maintain their cell-cell junctions, but the 
mechanisms that promote the motility are very similar to the single-cell migration. The 
leading cells, which may be the tumor cells themselves or stroma cells associated with 
the tumor, are responsible for localized proteolytic activity via secretion of MMPs 
(Friedl and Gilmour, 2009). Similar to single cell migration, collective cell migration is 
characterized by the formation of ruffles and pseudopodia, and the consequent 
attachment to the ECM via specific adhesion molecules. The main difference is that 
instead of retracting the rear, as happens to a single cell, the presence of cell-cell 
junctions creates pulling forces that make the mass move as a whole, while cells 
mostly keep their original conformation (Yilmaz and Christophori, 2010). A different 
form of collective migration is cell streaming, where single cells move by following one 
each other, but without keeping cell-cell contacts (Roussos et al., 2011). 
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1.2.4 The Ras superfamily of small GTPases  
 
The remodelling of the membranes and of the actin cytoskeleton in the cell requires a 
tight regulation and coordination. The Ras superfamily of small GTPases, comprising 
more than 150 members, is a major actor in these events. 
The ~150 members of the Ras superfamily of small GTPases can be divided into five 
families on the basis of their sequence as well as their functional similarities: Ras (the 
oncogene founding member), Rho, Rab, Ran and Arf (Wennerberg et al., 2005). There 
are also additional small GTPases, which are still considered as “unclassified”, as they 
do not show any of the features of the five major classes. These monomeric GTPases 
work as molecular switches via the binding of GDP/GTP to specific motifs. The switch 
to GTP enables these proteins to bind to their specific effector targets. 
Structurally, the N-terminus of these proteins is characterized by five conserved G box 
GDP/GTP-binding motif elements, the G motif, of about 20kDa. This domain is 
common not only among all the members of the Ras superfamily, but also to the Gα 
and other GTPases. The G motif includes the so-called “switch” domains I and II, which 
contain the residues responsible for the binding of the protein to GTP or GDP (Figure 
8).   
 
Figure	  8:	  Generic	  structure	  of	  a	  member	  of	  the	  Ras	  superfamily	  	  
 
The switch between the two nucleotides is regulated by two classes of proteins: GEFs 
(guanine-nucleotide exchange factor) and GAPs (GTPase activating protein). The 
former ones promote the exchange of GDP to GTP, thereby activating the ras family 
proteins (Cherfils and Chardin, 1999). The GAPs are responsible for the hydrolysis of 
GTP to GDP because the Ras proteins have a very low intrinsic GTPase activity 
(Bernards and Settleman, 2004). These small GTPases can have posttranslational 
lipid modification, which enables their binding to the plasma membrane or facilitates 
subcellular localization (Wennerberg et al., 2005).   
Among the Ras superfamily of small GTPases, the Arf proteins recently emerged as 
having a prominent role in regulating the actin cytoskeleton and the organization of 
focal complexes/adhesions (Turner et al., 2001). Therefore their activities and 
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regulation has become relevant for the understanding of both basic cell biology, as 
well as disease (D’Souza-Schorey and Chavrier, 2006) 
  
1.2.4.1 The Arf family of GTP-binding proteins  
The Arf (ADP rybosylation factor) proteins were first identified in 1984 as cofactors 
required for the cholera toxin-dependent ADP rybosylation of the Gs subunit regulating 
the adenylate cyclase (Kahn and Gilman, 1984). They are ubiquitously expressed in 
eukaryotic cells, where they have a major role in vesicle biogenesis, membrane 
trafficking and cytoskeletal organization (Pasqualato et al., 2002). One feature that 
makes these proteins unique is the N-terminal amphipathic helix, usually a myristoyl 
group (Colicelli, 2004). Another characteristic of the Arfs is the presence between 
switch I and II of an interswitch domain, that upon binding of GTP moves and displaces 
an amphipathic helix that becomes available for membrane insertion (Gillingham and 
Munro, 2007) (Figure 9).  
 
Figure	  9:	  Structure	  of	  Arf1,	  showing	  the	  conformational	  changes	  that	  occur	  after	  switching	  from	  GDP	  to	  GTP:	  the	  interswitch	  moves	  away	  from	  the	  GTP	  binding	  site	  and	  the	  amphipathic	  helix	  is	  free	  to	  bind	  the	  lipid	  bilayer	  of	  the	  membrane.	  
 
The six known mammalian Arf proteins are divided into three classes on the basis of 
their structure: class I, which includes Arf1, Arf2 (not present in humans) and Arf3; 
class II, which includes Arf4 and Arf5; Arf6 is the only member of class III. 
Arf1 and Arf6 are the most extensively studied and are involved in various cellular 
activities. Arf1 controls the formation of coat protein I (COPI)- coated vesicles of the 
Golgi – ER retrograde transport. It is also involved in the assembly of clathrin/adapter 
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protein 1 (AP1)–complex-associated vesicles at the trans-Golgi network and on 
immature secretory vesicles. Furthermore, Arf1 controls the formation of 
clathrin/adapter protein 3 (AP3)-containing endosomes (Wennerberg et al., 2005). 
Arf1 is also able to recruit the Golgi-localized γ-ear-containing Arf-binding proteins 
(GGAs) to the Golgi apparatus (D’Souza-Schroey & Chavrier, 2006).  
Arf6, which is absent from plants, controls endocytosis as well as the organization of 
the actin cytoskeleton at the cell periphery (Donaldson et al., 2003).  
 
1.2.4.2 The Arf GAP family 
The hydrolysis of the GTP in the Arf proteins is catalyzed by a class of GAPs specific for 
the Arfs, namely the Arf GAPs. In humans there are at least 31 genes that encode an 
Arf GAP domain (East and Kahn, 2011). The resulting proteins are divided on the basis 
of their other domains into two major groups, Arf GAP1 and AZAP, each containing 
proteins that differ in their specificity  (Figure 10) (Randazzo, Inoue and Bharti, 2007). 
 
 
 
Figure	  10:	  Schematic	  representation	  of	  Arf	  GAPs	  proteins	  and	  their	  characterizing	  domains:	  A	  (ankyrin	   repeats);	   SHD	   (Spa–homology	   domain);	   PBS2	   (paxillin-­‐binding	   site	   2);	   BAR	   (Bin,	  amphiphysin	   and	   Rvs	   161	   and	   167);	   PH	   (plekstrin	   homology);	   SAM	   (sterile	   α-­‐motif);	   GLD	   (GTP-­‐binding	  protein-­‐like	  domain)	  (adapted	  from	  Randazzo	  and	  Hirsch,	  2004)	  
 
The first group is the Arf GAP1 type, which has the Arf GAP domain at the immediate N-
terminus. This family includes six members, further divided into Arf GAP1 and Gits (G 
protein-coupled receptor kinase interactors). The Arf GAP1 subtype includes Arf 
GAP1/3 and SMAP1/2 (stromal membrane associated protein).  
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The Git1 and Git2 proteins have additionally three ankyrin (ANK) repeat domains 
immediately C-terminal of the Arf GAP domain, an SHD (Spa-homology domain) and a 
unique C-terminus, characterized by a PBS2 (paxillin binding site 2). 
The proteins belonging to the AZAP type (Arf GAP with ANK repeats and PH domains) 
have PH (plekstrin homology) domain immediately N-terminal and ANK repeats 
immediately C-terminal of the Arf GAP domain. The AZAP type is encoded by twelve 
genes, and the “Z” in the acronym corresponds in each of the four subtypes to the 
characterizing domain. For each subtype, three members have been identified.  
The ASAP sub-family is comprised of three members (ASAP1/DEF1/DDEF1/centaurin 
b4/AMAP1, ASAP2/PAP/AMAP2 and ASAP3/UPLC/DDEFL1/ACAP4). ASAP1 and 
ASAP2 contain a SH3 (Src homology 3) domain at the C-terminus. These subtypes also 
possess a BAR (Bin, amphiphysin and Rvs 161 and 167) domain at the N-terminus, 
which, by binding to the membrane, is able to bend it and may thus be involved in the 
endocytosis process. The ASAPs are characterized by a proline-rich domain that 
enables the binding to SH3-bearing proteins. There are at least three splicing variants 
of both ASAP1 and ASAP2, which lack one or more of these proline rich domains. 
ASAP3 does not have the SH3 domain, but is nevertheless included in this group 
because of the similarity of its domain structure, as well as phylogenetic analysis. The 
other AZAPs described in the literature are listed in Table 1. 
Name Characteristics 
ASAPs 
§ Proline rich domain 
§ ASAP1 and ASAP2 have SH3 and BAR domain 
ACAPs § Predicted coiled-coil domain in the N-terminus 
AGAPs 
§ GLD (GTP-binding protein-like domain) in the N-terminus 
§ Split PH domain 
ARAPs 
§ Rho GAP domain 
§ SAM (sterile α-motif) 
 
Table	  1:	  The	  AZAP	  families	  and	  their	  characteristics	  
 
Among these Arf GAPs, ASAP1 has emerged from work in our laboratory, as well as 
that of others, as being a protein that is involved in the promotion of motility and 
invasiveness in vitro, and that contributes to metastasis formation in vivo (Ehlers et al., 
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2005; Onodera et al., 2005; Lin et al., 2008; Müller et al., 2010). This protein was the 
focus of my PhD studies.  
 
1.3 ASAP1 
 
1.3.1 Structure of ASAP1 
 
As already mentioned, ASAP1 belongs to the Arf GAP family, type AZAP. ASAP1 
contains a BAR and a PH domain, a zinc finger, three ankyrin repeats, a proline rich 
region that contains alternative splicing regions and SH3 binding motifs, eight repeats 
of the sequence E/DLPPKP, and a SH3 domain (Figure 11). Each domain contributes 
to the features of ASAP1 by enabling it to bind to various proteins and cellular 
structures, thereby defining its subcellular localization and its activity. ASAP1 is found 
in peripheral FAs, but moves to the cell edge during cell spreading (Randazzo et al., 
2000). It localizes also to the cytoplasm in a perinuclear reticular network (Brown et 
al., 1998). 
 
Figure	  11:	  Schematic	  picture	  showing	  the	  structure	  of	  ASAP1	  and	  its	  domains	  
 
Via the BAR domain ASAP1 is able to bind to acid phospholipids of the plasma 
membrane, and has therefore a role in membrane trafficking (Nie et al., 2006). The 
BAR domain seems to be also involved in the formation of podosomes (Bharti et al., 
2007), one of the cytoskeletal structures in which ASAP1 is involved. 
ASAP1 binds phosphatidyl-inositol-4,5-bisphosphate (PIP2) through the PH domain, 
which is required for the Arf GAP activity of ASAP1, together with the Arf GAP domain 
(Che et al., 2005). The Arf GAP domain consists of ~140 residues, four of which are 
invariable cysteines that coordinate a zinc ion (Goldberg et al., 1999; Mandiyan et al., 
1999). Together with the ankyrin repeats, these three domains form the so-called PH-
Zn-finger-ANK (PZA) motif, which is conserved in plants, worms and flies, suggesting 
the importance of this module. These domains provide the Arf GAP activity of ASAP1, 
which is specific for Arf1 and Arf5, to a lesser extent to Arf6 (Brown et al., 1998). 
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The ankyrin repeats (one of the most common protein–protein interaction motifs), the 
proline-rich regions and the SH3 domain are all motifs that enable the binding of 
ASAP1 to a plethora of proteins, that regulate and mediate the variety of cellular 
processes that ASAP1 is involved in. 
There are two splicing variants identified in humans, ASAP1a and ASAP1b, the latter of 
which misses part of the proline-rich region. In our laboratory we identified a third 
splicing variant, rASAP1c, which has an even shorter proline-rich region and lacks a 
sequence of 15 amino acids between the BAR and the PH domain. These variations 
however do not impair the binding of ASAP1 to its partner proteins, nor the Arf GAP 
activity (Müller et al., 2010). 
 
1.3.2 Roles of ASAP1 in the cell 
 
1.3.2.1 Regulation of the actin cytoskeleton 
ASAP1 plays a role in the regulation of the actin cytoskeleton, in particular via its 
association with four cytoskeletal structures: focal adhesions, circular dorsal ruffles 
(CDRs), and invadopodia/podosomes (Randazzo et al., 2007). ASAP1 associates with 
these structures via binding to other proteins that are part of these structures. 
The localization of ASAP1 is mainly in peripheral FAs (Randazzo et al., 2000) due to its 
interaction with Crk/CrkL (chicken tumor virus 10 regulator of kinase/Crk-like) via its 
proline-rich regions (Brown et al, 1998; Oda et al., 2003) and with FAK via the SH3 
domain (Liu et al., 2002). The overexpression of ASAP1 causes a change in the 
localization of these two proteins to the cytosol, reducing their stable association in 
the focal adhesions (Liu et al., 2002). The same does not happen if a SH3 domain 
mutant or a form lacking the GAP activity is used, suggesting a role of ASAP1, and in 
particular of its GAP activity, in focal adhesion dynamics. 
Circular dorsal ruffles form transiently upon stimulation of the cell with various 
agonists, for example PDGF (Buccione et al., 2004). Randazzo and co-workers 
demonstrated that ASAP1 co-localizes with these structures and regulates the actin 
cytoskeleton (Randazzo et al., 2000). In fact, overexpression of ASAP1 in fibroblasts 
caused a slowing down of cell spreading, as well as a decreased formation of dorsal 
ruffles upon stimulation with PDGF. This effect is dependent on the Arf GAP domain of 
ASAP1, as demonstrated by using a mutant form lacking this activity (Randazzo et al., 
2000). Moreover, the localization of ASAP1 in the cell also contributes to the 
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regulation of cytoskeletal remodelling. For example, the mislocalization of ASAP1 to 
the mitochondria prevents efficient cell spreading on fibronectin. The same was 
observed when ASAP1 was silenced (Liu et al., 2005). A role for ASAP1 in the 
regulation of cell motility is also indicated by an increase in migration towards PDGF 
when ASAP1 is over expressed (Furman et al., 2002). 
ASAP1 also binds to the ubiquitous adaptor protein CD2AP (CD2-associated protein) in 
membrane ruffles (Liu et al., 2005). CD2AP possesses three SH3 domains at its N-
terminus, and binds to ASAP1 via the first two. Interestingly, CD2AP binds cortactin, 
another binding partner of ASAP1, in breast cancer cells stimulated by EGF, and co-
localizes with ASAP1 in membrane ruffles (Lynch et al., 2003). Cortactin, a component 
of invadopodia/podosomes is also able to bind to ASAP1 via its SH3 domain (Onodera 
et al., 2005). This protein is encoded by the EMS1 gene in the 11q13 amplicon, a 
region commonly amplified in 13% of primary breast cancers and 30% of head and 
neck squamous cell carcinomas of the head and neck (Schuuring et al., 1992; Fantl et 
al., 1993; Williams et al., 1993; Karlseder et al., 1994; Peters et al., 1995).   
ASAP1 is also a component of podosomes, and its presence is necessary for the 
formation of these structures (Bharti et al., 2007). This role is not due to the Arf-GAP 
activity. Instead, phosphorylation of ASAP1 on Tyr 782 and the SH3 domain are 
necessary for podosome formation. The phosphorylation is mediated by Src, another 
binding partner of ASAP1 (Bharti et al., 2007).  
Src is also a fundamental component of invadopodia, another cytoskeletal structure 
ASAP1 participates in (Bharti et al., 2007), and is one of the proteins required for 
invadopodia-mediated matrix degradation in a variety of tumor cell lines (Stylli et al., 
2008). The BAR domain of ASAP1 also seems to play role in invadopodia formation, 
although it is still not clear how (Bharti et al., 2007). Interestingly, ASAP1 also binds via 
the BAR domain to GEFH1, a GEF for Rho A which inhibits the formation of podosomes 
(Shiba and Randazzo 2011). As the BAR domain inhibits the GAP activity of ASAP1 
(Jian et al., 2009), it is plausible that the binding of GEFH1 results in a reduced 
binding to Arf, and thus to a reduction in podosome formation.  
Pyk2 (Proline-rich tyrosine kinase 2), a non-receptor tyrosine kinase related to FAK, is 
also able to bind ASAP1 (Kruljac-Letunic et al., 2003), but unlike FAK, Pyk2 is localized 
in the cytoplasm and concentrated in perinuclear regions (Matsuya et al. 1998). It acts 
upstream of small G-proteins, linking transmembrane receptors to MAPK pathways. 
The binding of ASAP1 to Pyk2 is mediated by the SH3 domain of ASAP1 and the 
 32 
proline-rich region of Pyk2. Upon binding, ASAP1 can be phosphorylated by Pyk2, and 
this results in a reduction of its GTPase activity (Kruljac-Letunic et al., 2003). The 
effect of this interaction in the regulation of the cytoskeleton is still unclear. 
 
1.3.2.2 Vesicle trafficking and receptor internalization 
Arf1, one of the substrates of ASAP1, is the main regulator of the trafficking of lipids 
and protein between the membrane-delimited organelles (Balch et al., 1984a; 1984b). 
By exchanging GDP with GTP, Arf1 binds to the membrane, and can recruit several 
coat proteins that bind to and concentrate cargo. Arf GAPs like ASAP1 are also 
recruited, and may bind both to coat proteins and to the cargo without hydrolysing the 
GTP on the Arf protein (Nie and Randazzo, 2006). Coat proteins are able to deform 
membranes and thus to promote the budding and eventually the fission of the vesicle 
(Bonifacino and Glick, 2004). The hydrolysis of GTP catalysed by the Arf GAP causes 
the dissociation of Arf from the membrane, leaving the newly formed vesicle free to 
fuse with acceptor membranes (Figure 12) (Nie and Randazzo, 2006a).  
 
Figure	   12:	   Mechanism	   of	   vesicle	   fission	  mediated	   by	   Arf	   and	   Arf	   GAPs	   (adapted	   from	   Nie	   and	  Randazzo,	  2006)	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In accordance with its role as an Arf GAP protein, there is quite a body of literature 
connecting ASAP1 with vesicle trafficking and receptor internalization. Interestingly, 
this feature is often connected with the regulation of the cytoskeleton, as exemplified 
by the interaction of CIN85 (Cbl-interacting protein of 85kDa) with ASAP1 in 
invadopodia (Nam et al., 2007).  
Via its BAR domain ASAP1 is able to dimerize and subsequently bind to 
phosphoinositides in the plasma membrane via its PH domain. This interaction, 
together with binding to Arfs present on the membrane, causes bending of the 
membrane (Figure 13). ASAP1 is thus able to tubulate membranes in vivo, and 
therefore may be able to generate vesicles  (Nie and Randazzo, 2006). For example, 
depletion of ASAP1 led to an accumulation of transferrin and transferrin receptor to 
the cell edge, instead of the usual perinuclear localization, in a compartment 
containing Rab11 and FIP3 (Inoue et al., 2008). These proteins are typical recycling 
endosomes markers, and ASAP1 binds to FIP3 via its BAR domain (Inoue et al., 2008). 
 
	  
Figure	  13:	  Via	  specific	  domains,	  ASAP1	  is	  able	  to	  dimerize	  and	  bind	  to	  the	  plasma	  membrane,	  
bending	  it	  to	  facilitate	  receptor	  endocytosis	  (adapted	  form	  Nie	  et	  al.,	  2006b)	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1.3.3 ASAP1 and cancer 
 
1.3.3.1 Roles of ASAP1 in tumor development and progression 
ASAP1 has been first linked to cancer in our laboratory. It was found in an unbiased 
screen for genes associated with metastasis that we performed (Nestl et al., 2001). 
Later Onodera and colleagues showed that the protein levels of ASAP1 correlate with 
the invasiveness of different human breast cancer cells (Onodera et al., 2005). In their 
model, ASAP1 was able to bind both cortactin and paxillin via the SH3 domain, forming 
a trimeric complex that was detectable only in highly invasive cell lines. In the same 
year, a potential role for ASAP1 as an oncogene in uveal melanoma was suggested 
(Ehlers et al., 2005). This pathology is usually accompanied by an amplification of the 
8q chromosome, where ASAP1 is located. Indeed, they showed that both mRNA levels 
and protein expression were significantly enhanced in high-grade melanomas. 
Furthermore, ectopic expression of ASAP1 in low-grade melanoma cells resulted in a 
significant increase in cell motility, a feature of high-grade metastasizing cells (Ehlers 
et al., 2005). 
Overexpression of ASAP1 has been also linked to prostate cancer (Lin et al. 2008). A 
metastatic and a non-metastatic subline were derived from the same prostate cancer 
tissue and gene expression was compared. Both ASAP1 mRNA and protein were 
expressed at a significantly higher level in a metastatic tumor subline, compared to the 
non-metastatic one.    
Following up on our observation that ASAP1 belongs to a group of genes whose 
expression is exclusive to or at least upregulated in metastatic mammary, pancreatic 
and prostate cells lines (Nestl et al., 2001), our laboratory found that ASAP1 
expression correlated with tumor progression in a number of cancers, and that the 
expression of ASAP1 functionally regulates metastatic potential in rat tumor models 
(Müller et al., 2010).  Moreover, the staining of several human tumor tissues 
(carcinomas of stomach, colon, gall bladder, breast, bladder and ovary, papillary 
carcinoma of the thyroid, and esophageal, head and neck squamous cell carcinomas) 
showed the presence of ASAP1, which was not present in the corresponding healthy 
tissues (Figure 14). The analysis of tumor material obtained from patients with colon 
adenocarcinomas revealed that the expression of ASAP1 in the patients that 
developed metachronous metastases was significantly higher, again underlying the 
relevance of ASAP1 to tumor progression. In patients with colorectal adenocarcinomas 
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the expression of ASAP1 is correlated with a short metastasis-free survival, as well as 
with a poor overall survival (Müller et al., 2010).  
 
 
 
	  
Figure	   14:	   Expression	   of	   ASAP1	   in	   human	   tumors.	  Normal	  esophageal,	  colorectal,	  and	  thyroid	  tissues	  (a,	  c,	  and	  e,	  respectively)	  and	  their	  corresponding	  tumors	  (b,	  d,	  and	  f,	  respectively)	  were	  immunostained	  using	  the	  7B12	  antibody	  and	   AEC	   (red	   color),	   followed	   by	   counterstaining	   with	  hematoxylin	  (blue	  color)	  (Müller	  et	  al.,	  2010)	  	  
 
 
1.3.3.2 Role of the proline-rich domain in ASAP1  
As already mentioned, the proline rich region of ASAP1 is able to bind to several 
proteins involved in the control of cell motility, such as c-src and Crk (Brown et al., 
1998). Our laboratory showed that a mutant form of ASAP1 containing a point 
mutation in this region (R811A) is unable to promote in vitro wound healing and 
migration in contrast to the wild type ASAP1 protein (Figure 15) (Müller et al., 2010). 
	  
Figure	   15:	   Wound	   healing	   and	   migration	   assays.1AS	   rat	   pancreatic	   cells	   transiently	   transfected	  with	  empty	  vector,	  wild	  type	  ASAP1	  or	  the	  mutant	  R811A	  were	  used	  for	  A.	  wound	  healing	  assay	  and	  B.	  invasion	  assay	  (Müller	  et	  al.,	  2010)	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Consistently, only animals bearing tumors derived from pancreatic cancer cells that 
were engineered to express the wild type form of ASAP1 were able to develop lung 
metastasis, whereas the animals bearing tumors derived from pancreatic cancer cells 
that expressed the mutated form behaved comparably to the control tumors and did 
not develop lung metastasis (Figure 16) (Müller et al., 2010).  
 
Figure	   16:	   1AS	   rat	   pancreatic	   cells	   stably	   transfected	   with	   the	   vectors	   indicated	   and	   injected	   in	  syngeneic	  animals.	  The	  graph	  shows	  the	  effect	  on	  the	  formation	  of	  lung	  metastasis	  (Müller	  et	  al.,	  2010)	  
 
These results strongly indicate that the interaction of ASAP1 with SH3 domain bearing 
proteins through its proline rich regions plays an important role in the promotion of 
motility and metastasis. 
 
1.3.3.3 The EGFR-ASAP1 pathway in breast cancer 
A variety of observations suggest that ASAP1 plays an important regulatory role in the 
recycling and signalling of EGFR, and by this means may contribute to the invasiveness 
of tumor cells. For example, Arf1 is involved not only in internal vesicle trafficking, but 
also has a prominent role in the internalization of receptors such as EFGR in breast 
cancer cells, thereby influencing the PI3K pathway and the subsequent motility and 
invasive properties of the cells (Boulay et al., 2008). Through modulating Arf1 activity, 
ASAP1 likely functions as a key regulator of EGFR signalling.  
 
Other protein interaction partners of ASAP1 are also involved in EGFR regulation. For 
example, CIN85 is an adaptor protein that via its SH3 domains binds the ubiquitin 
ligase Cbl, and together they down-regulate EGF receptors (Haglund et al., 2002). 
ASAP1 is able to interact with CIN85 via its proline rich regions, participating in the 
regulation of receptor recycling. In fact, overexpression of ASAP1 led to an increase in 
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receptor recycling in CHO cells, which was specific for EGFR (Kowanetz et al., 2004). 
Increased internalization and recycling of the EGFR receptor has been shown to be 
particularly important in the promotion of cell motility and invasive potential. In cancer 
cells expressing mutant p53, the recycling of integrins and EGFR is enhanced, and this 
results in an increase in cell migration and invasion (Muller et al., 2009). 
 
In addition, EGFR signals to ASAP1 to stimulate formation of invadopodia. Arf6 uses 
ASAP1 as an effector, is over expressed in highly invasive breast cancer cells, and 
plays an important role during invasion (Sabe et al., 2006). GEP100 is the specific GEF 
for Arf6, and its knock down inhibits the formation of invadopodia in MDA MB 231 
cells. In these cells GEP100 binds the phosphorylated tyrosines of the activated EGF 
receptor via its PH domains and activates Arf6 (Morishige et al., 2007). The active Arf6 
recruits ASAP1 to the plasma membrane, where they co-localize in invadopodia, as 
well as to cytoplasmatic large vesicles (Hashimoto et al., 2005). The binding of ASAP1 
to Arf6 is stable and does not lead to immediate hydrolysis of GTP. The recruitment of 
ASAP1, together with other protein such as cortactin and paxillin, is the starting point 
for the formation of invadopodia (Figure 17). Therefore the activation of EGFR 
stimulates the formation of invadopodia in a manner that is dependent on ASAP1.  
 
 
Figure	  17:	  The	  EGF-­‐GEP100	  pathway	  links	  ASAP1	  with	  the	  formation	  of	  invadopodia.	  
 
Another study links EGFR, integrins (β1 in particular) and ASAP1. Onodera et al. 
showed how the signalling of EGFR induces the activation of Arf6 and the subsequent 
recruitment of ASAP1 to the plasma membrane. This forms a complex with the protein 
kinase D1 (PKD1) and the β1 integrin to promote its recycling and thus increase the 
invasiveness of breast cancer cells (Onodera et al., 2012) 
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1.3.4 New interaction partners 
 
ASAP1 is a multidomain protein, and is therefore able to bind to several partners. Its 
role in promoting motility and metastasis has already been shown (Onodera et al., 
2005; Müller et al., 2010), but the mechanisms are still unclear. In particular it has 
still to be elucidated which of the many ASAP1-interacting proteins contribute to this 
activity. In collaboration with Prof. Zollo who works on h-prune and Nm23-H1, our lab 
obtained evidence from co-immunoprecipitation experiments that indicated a physical 
interaction between ASAP1 and both h-prune (Müller et al., 2010) and Nm23-H1 
(Figure 18), possibly suggesting the presence of a ternary complex able to regulate 
metastasis formation.  
 
Figure	  18:	  Western	   blot	   pictures	   showing	   the	   co-­‐immunoprecipitation	   of	   ASAP1	  with	   both	   h-­‐prune	  (upper	  blots)	  and	  Nm23-­‐H1	  (lower	  blots)	  (Zollo	  lab,	  unpublished	  results;	  Müller	  et	  al.,	  2010).	  
 
1.3.4.1 h-prune 
The human prune (h-prune) gene is the orthologue of the Drosophila prune gene 
involved in development of the eye color. In the case of a homozygous mutation in this 
gene, the eyes of Drosophila are purple-brownish instead of red. There is no effect on 
viability or fertility, but this mutation (both hemi- or homozygous), when present with a 
single copy mutation of the abnormal wing disc (awd) gene (awdK-pn, killer-of-prune), is 
lethal (Timmons and Shearne, 1996). The awd gene is the Drosophila orthologue of 
the Nm23-H1 protein described below. 
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H-prune belongs to group II of the DHH (Asp-His-His) phosphoesterase superfamily, 
and possesses a PDE (phosphodiesterase) activity that is able to induce cell motility in 
breast cancer cells (D’Angelo et al., 2004). Recently, it has been shown that h-prune 
also possesses an exopolyphosphatase activity (PPase) (Tammenkoski et al. 2008), 
and that both of these activities could be potential therapeutic targets. For example, 
the treatment of MDA-MB-234 breast cancer cells with dipyridamol, a potent inhibitor 
of the h-prune PDE activity, was able to reduce cell motility (D’Angelo et al., 2004).  
In addition to the DHH motif at the N-terminus, there is a less conserved DHHA2 
domain that provides substrate-binding residues and therefore influences specificity. 
The C-terminal region includes a cortexillin homology domain with putative coiled-coil 
and proline rich regions. GSK-3β is able to bind to h-prune through this domain 
(residues 330-453), and together they regulate the disassembly of focal adhesions 
and thereby promote cell migration. H-prune has also been reported to bind to 
gelsolin, a molecule involved in cytoskeleton remodeling. Consistent with a role in 
promoting cell motility, the h-prune protein has been found to be expressed at higher 
levels in breast (D’Angelo et al., 2004), colorectal (Forus et al., 2001), and gastric 
carcinomas (Kobayashi et al., 2006), promoting both tumour invasiveness and 
metastasis formation. Amplification of h-prune copy number induces cell proliferation 
in an established breast cancer cell model (Reymond et al., 1999). The metastasis 
promoting activity of h-prune is further enhanced by the binding with Nm23-H1, as 
described below.  
 
1.3.4.2 Nm23-H1 
Nm23-H1 belongs to a family of nucleoside diphosphate kinases (NDPK) and is 
encoded by one of the ten Nm23 human genes (Marino et al., 2011). The members of 
group I (NME1-4) are ubiquitously expressed, and are found mainly in the cytoplasm, 
except for NME4, which is localized to the mitochondria (Tokarska-Schlattner et al., 
2008). They are all hexameric and possess NDPK activity (Lacombe et al., 2000). In 
group II, the enzymatic activity has only been demonstrated for the product of NME6, 
which is also the only member of this group that is not expressed in ciliated structures 
(Tsuiki et al., 1999). The Nm23/NDPKs have several roles in proliferation, 
differentiation, development, cytoskeleton dynamic, endocytosis, apoptosis and cell 
signalling (wnt, p53, GTPases) (Boissan et al., 2009). 
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In 1988 Steeg and co-workers were able to show that the expression of NM23 was 
significantly higher in a low metastatic cell line compared to a high one, suggesting a 
role as a metastasis suppressor for the Nm23-H1 protein (Steeg et al., 1988). 
Nevertheless, the mechanism underlying this feature is still not completely 
understood. It is also known as NDPK-A (nucleotide diphosphate kinase-A), due to the 
enzymatic activity that it possesses (Biggs et al., 1990, Wallet et al., 1990), but this 
well-characterized activity has never been correlated with its metastasis suppressing 
effects (MacDonald et al., 1993). In addition to the NDPK activity, Nm23-H1 also 
possesses a histidine kinase activity, via the very same phosphohistidine (H118) that 
mediates the phosphorylation of nucleoside 5'-diphosphates to triphosphates. At least 
three substrates for this enzymatic activity have been identified: ATP-citrate lyase 
(Wagner et al., 1995), aldolase C (Wagner et al., 2000) and the kinase suppressor of 
Ras (KSR) (Hartsough et al., 2002) (Figure 19). The physiological effects of the 
phosphorylation on the first two proteins are still unknown. KRS is a scaffold protein 
for the MAP kinase pathway, recruiting several proteins to the cell membrane. The 
phosphorylation of its serines 392 and 434 by Nm23-H1 causes a degradation of the 
KRS protein and a consequent decrease in pErk activity in tumor cells (Hartsough et 
al., 2002). 
 
Figure	   19:	   	   The	   histidine	   kinase	   activity	   of	   Nm23-­‐H1.	   The	   autophosphorylation	   of	   Nm23-­‐H1	  activates	  its	  histidine	  kinase	  activity	  on	  three	  substrates,	  as	  shown	  in	  this	  picture:	  KSR,	  aldolase	  C	  and	  ATP	  citrate	  lyase	  (adapted	  from	  Steeg	  et	  al.,	  2008)	  
 
Recently it has been shown that Nm23-H1 also possesses a 3’-5’ exonuclease activity, 
which is associated with proofreading processes during DNA repair and replication (Ma 
 41 
et al., 2004). This activity seems to be required for the metastasis suppressor function 
of Nm23-H1, (Zhang et al., 2011), which is not surprising, considering that reduced or 
absent expression of 3’-5’-exonucleases has been associated with increased cancer 
progression (Jackson and Loeb, 1998).  
A plethora of binding partners of Nm23-H1 have been reported, underlying the crucial 
role of this protein in many cellular processes (Marino et al., 2011). For example, 
Nm23-H1 binds to various GEFs such as Tiam1 (Otsuki et al., 2001), Lbc (Iwashita et 
al., 2004) and Dbl (Murakami et al., 2008a; 2008b) as well as to members of the Ras 
family of small GTPases: Arf6 (Palacios et al. 2002) and Rad (Tseng et al., 2001). 
Nm23-H1 is also able to bind to receptors (ER, RORα/RZR) and transcription factors 
(EBNA1-3C, Oct transcription factor complex and SET), thereby regulating some of the 
transcriptional complexes involved in metastasis formation (Curtis et al., 2007; 
Paravicini et al., 1996; Subramanian et al., 2001; Zheng et al., 2003; Fan et al., 
2003). Finally, Nm23-H1 is also involved in cytoskeletal regulation through binding to 
vimentin, tubulin, Icap-1α and plakoglobin (Otero et al., 1997; Otero, 2000; Pinon et 
al. 1999; Lombardi et al., 1995; Fournier et al., 2002; Aktary et al., 2010). 
 
1.3.4.3 h-prune and Nm23-H1 interaction in cancer 
The interaction of the human Nm23-H1 with h-prune was first demonstrated in 1999 
by Reymond et al. by using in vitro co-immunoprecipitations (Reymond et al., 1999). 
This binding was then confirmed and analyzed in further studies that also 
characterized the PDE activity of h-prune and its relevance in regulating cell motility 
(D’Angelo et al., 2004). There is a direct correlation between the interaction of h-prune 
with Nm23-H1 and the increase in the PDE activity of h-prune. Zollo and co-workers 
have shown that the overexpression of h-prune in cancer cells leads to an increase in 
motility, and thus in metastatic potential, via the binding of Nm23-H1. Indeed, h-prune 
is able to act as a negative regulator of the anti-metastatic activity of Nm23-H1 in two 
ways. On the one hand, high levels of h-prune in the cell sequester the free Nm23-H1, 
whose metastasis suppressing activity is therefore reduced. In parallel, the binding of 
Nm23-H1 to h-prune causes an increase in the PDE activity of h-prune, which leads to 
an overall increase in cellular motility (Figure 20).   
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Figure	  20:	  Schematic	  representation	  of	  the	  interaction	  of	  h-­‐prune	  and	  Nm23-­‐H1	  in	  tumor,	  and	  
the	  effects	  of	  this	  binding.  
	  
The region that interacts with h-prune is the carboxyl terminus of Nm23-H1, around 
S120, S122 and S125. The phosphorylation of these serines by casein kinase I (CKI) 
is essential for the binding of h-prune to Nm23-H1 (Garzia et al., 2008). Indeed, 
treatment with IC261, an inhibitor of CKI, is able to disrupt the complex, identifying a 
further potential therapeutic approach together with the PDE inhibitor dipyridamol 
(Figure 21). 
 
 
 
Figure	   21:	   The	   interaction	   between	   Nm23-­‐H1	   and	   h-­‐prune	   and	   the	   subsequent	   metastasis	  
promoting	  effects	  can	  be	  impaired	  by	  the	  use	  of	  a	  CKI	  inhibitor	  and	  dipyridamol.	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2. AIMS OF THE STUDY 
 
ASAP1 is a multidomain adaptor protein that is involved in several physiological 
processes such as cytoskeletal re-organization (Randazzo et al., 2000) and vesicle 
trafficking (Nie et al., 2006). ASAP1 has also been shown to play a role in tumor 
development (Lin et al., 2008) and progression (Morishige et al., 2008; Müller et al., 
2010). ASAP1 is able to bind to several SH3 bearing proteins via its proline rich 
regions that may mediate its activities, in particular the promotion of motility and 
invasiveness, and thus of metastasis formation. ASAP1 has been shown by the 
laboratory of Prof. Zollo to interact also with Nm23-H1 and h-prune, a protein duo 
involved in cell motility and invasion. The aim of my study was to investigate if and to 
which extent these binding partners of ASAP1 are able to affect its metastasis-
promoting activities. For this purpose I chose two prominent features of ASAP1, 
namely its role in vesicle trafficking and growth factor internalization, as well as its 
ability to promote motility. The specific aims of my study were as follows: 
- Establish an assay for measuring the internalization of EGF in the highly invasive 
model of the MDA MB 231 cells 
- Investigate the possible effects of the two new binding partners of ASAP1, Nm23-
H1 and h-prune, on the uptake of EGF and the motility promoted by ASAP1 
- Identify additional SH3 domain-bearing proteins that bind to ASAP1, and then 
analyze the possible interference of Nm23-H1 and h-prune with this binding  
- Evaluate the influence of SH3-domain ASAP1 binding partners on the motility-
promoting activity of ASAP1. 
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3. MATERIALS AND METHODS 
 
3.1 Instruments 
 
Centrifuges Thermo Fisher Scientific, Schwerte 
Developer for X-ray films CAWOMAT 2000R CAWO, Schrobenhausen  
Diaphragm Pump Vacuubrand, Wertheim 
Electrophoresis Apparatus  PeqLab, Erlangen; BioRad, München 
ELISA reader Multiskan Acscent Thermo Fisher Scientific, Schwerte 
FACS-can  BectonDickinson, Franklin Lakes USA 
Fluorescence microscope Axio Imager D1 Carl Zeiss, Jena 
FPLC system GE Heathcare, München 
Gel dryer  MGD 5040 VWR International, UK 
Incubator  Binder, Tuttlingen 
Incubator HeraCell Thermo Fisher Scientific, Schwerte 
Microscope Axiovert 40 CFL Carl Zeiss, Jena 
NanoDrop PeqLab, Erlangen 
PCR-Cycler Analytikjena, Jena 
Shaker for bacteria Certomat IS Sartorius, Göttingen 
Sonicator Sonoplus Bandelin, Berlin 
Sterile hood Hera Safe Thermo Fisher Scientific, Schwerte 
Thermomixer 5436 Eppendorf, Hamburg 
Ultracentrifuge Sorval RC6 plus Thermo Fisher Scientific, Schwerte 
UV-Transiluminator  INTAS, Göttingen  
Vortex  VWR International, UK 
Water bath Memmert, Büchenbach 
 
3.2.Chemicals, reagents and consumables 
 
0.25% Trypsin-EDTA (1x), phenol red Life Technologies, Darmstadt 
AceGlow PeqLab, Erlangen 
Acetic acid  Roth, Karlsruhe 
Acrylamide/N,N‘-Methylenbisacrylamide (37,5:1)  Roth, Karlsruhe 
Agarose  Biozym, Wien, Austria 
Ammonium peroxodisulfate (APS)  Roth, Karlsruhe 
Ampicillin  Roth, Karlsruhe 
BCA assay Thermo Fisher Scientific, Schwerte 
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Bovine serum albumin (BSA)  PAA, Pasching, Austria 
Bromophenol blue Roth, Karlsruhe 
Butanol Roth, Karlsruhe 
Chloroform  Roth, Karlsruhe 
Coomassie Brilliant Blue R250  Roth, Karlsruhe 
Deoxynucleoside-triphosphates (dNTPs) Life Technologies, Darmstadt 
Diethylpyrocarbonate (DEPC)  Roth, Karlsruhe 
Dimethylsulfoxide (DMSO)  Sigma Aldrich, Steinheim 
Dithiothreitol (DTT)  Fluka, Neu-Ulm 
Dulbecco‘s modified Eagle Medium (DMEM)  Life Technologies, Darmstadt 
ECL-Western blotting detection reagent Thermo Fisher Scientific, Schwerte 
Ethidium bromide  Roth, Karlsruhe 
Ethylenediaminetetraacetic acid (EDTA)  Sigma Aldrich, Steinheim 
Fetal Calf Serum (FCS)  Life Technologies, Darmstadt 
Glycerol  Sigma Aldrich, Steinheim 
Glycine  Roth, Karlsruhe 
HEPES Roth, Karlsruhe 
Lipofectamine 2000 Life Technologies, Darmstadt 
Lipofectamine LTX Life Technologies, Darmstadt 
Lithium chloride Roth, Karlsruhe 
Magnesium chloride Roth, Karlsruhe 
Methanol Roth, Karlsruhe 
N, N, N‘, N‘-Tetramethylethylendiamine (TEMED)  Roth, Karlsruhe 
Oligonucleotides  Metabion 
OptimMem Life Technologies, Darmstadt 
Paraformaldehyde  J.T. Baker, Deventer, The Netherlands 
Penicillin/Streptomycin  Life Technologies, Darmstadt 
Phenol  Roth, Karlsruhe 
Phenylmethylsulfonyl fluoride (PMSF) Roth, Karlsruhe 
Phosphate buffer saline (PBS) Life Technologies, Darmstadt 
Plasmid Maxi Kit  Qiagen, München 
Propanol Roth, Karlsruhe 
Protein G+ Agarose Calbiochem, Darmstadt 
Reagents for developer AGFA, Bonn 
Restriction enzymes and buffers Fermentas, Thermo Fisher Scientific, Schwerte 
SOC Life Technologies, Darmstadt 
sodium acetate  Roth, Karlsruhe 
sodium chloride Roth, Karlsruhe 
sodium orthovanadate Roth, Karlsruhe 
sodium dodecylsulfate (SDS)  Roth, Karlsruhe 
sodium hydroxide (NaOH)  Roth, Karlsruhe 
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Superscript II Life Technologies, Darmstadt 
T4-Ligase  Fermentas, Thermo Fisher Scientific, Schwerte 
Taq-DNA-Polymerase and Buffer  Fermentas, Thermo Fisher Scientific, Schwerte 
Tip-500-columns  Qiagen, München 
TOPO-TA-Cloning Kit  Life Technologies, Darmstadt 
Tris-HCl, Tris-Base  Sigma Aldrich, Steinheim 
Triton X-100  Sigma Aldrich, Steinheim 
Trizol Life Technologies, Darmstadt 
Tryptone Roth, Karlsruhe 
Tween 20  GE Heathcare, München 
Yeast extract Roth, Karlsruhe 
 
3.2.1 Antibodies 
 
3.2.1.1 Primary antibodies 
Anti-ASAP1       mouse, monoclonal, self-production 
Anti-FLAG-M2       mouse, monoclonal, Sigma 
Anti-Nm23-H1      mouse, monoclonal, Abcam 
Anti-HA       mouse, monoclonal, Covance 
Anti-SLK      rabbit, polyclonal, Abcam 
Anti-His       rabbit, polyclonal, MicroMol 
Anti-β-actin      mouse, monoclonal, Sigma 
Anti-cortactin      mouse, polyclonal, Millipore 
Anti-GST (clone 2D5)     rat, self production 
Anti-TNP      mouse, self prooduction 
 
3.2.1.2 Secondary antibodies 
All secondary antibodies were from DAKO, polyclonal, produced in goat 
Anti mouse HRP 
Anti rabbit HRP 
Anti Rat HRP 
 
3.2.2 Oligonucleotides 
 
huHPRT (Hypoxanthine–Guanine Phosphoribosyltransferase) primers 
forward: 5´- CCAAAGATGGTCAAGGTCGC- 3´ 
reverse: 5´- CTGCTGACAAAGATTCACTGG - 3´ 
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huASAP primers 
forward: 5´- GCCACCATGAGATCTTCAGCCTCCA- 3´ 
reverse: 5´- CTGCGTTTTGCTAGTCAGACAGGATATG- 3´ 
 
Cloning of human SLK 
forward: 5´- CACCATGTCCTTCTTCAATTTCCG - 3´ 
reverse: 5´-TGA TCC GGT GGA ATG CAA GCT GGG AAT- 3´ 
 
3.2.3 Cells  
 
3.2.3.1 Prokaryotic cells 
One Shot® TOP10 Chemically Competent E. coli  (Invitrogen) 
XL1-Blue E. coli   
 
3.2.3.2 Eukaryotic cells  
NAME SPECIFICATION REFERENCE 
MDA MB 231 Human breast adenocarcinoma Brinkley et al., 1980 
Hek293 Human embryonic kidney Graham et al., 1977 
7B12 Mouse hybridoma cells 
Self production (Müller et al., 
2010) 
Primary mouse embryonic 
fibroblasts 
 Self purification 
 
3.3 Cell culture methods 
 
3.3.1 Eukaryotic cell maintenance 
 
Except for primary mouse embryonic fibroblasts (MEFs), all mammalian cells used in 
this study were maintained at 37°C in an incubator in 5% CO2 and 95% air humidity. 
The MEFS were kept for a maximum of 6 passages under the same conditions as the 
other cells, but with a constant 3% of O2. Cells were grown in Petri dishes, multi well or 
flasks of varying size depending on the application. Both culture medium and trypsin 
were warmed to 37°C before applying them to the cells. 
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In general, the cells were grown until a confluency of 80-90% had been reached, 
detached by trypsinization and re-seeded at lower density. Briefly, culture medium was 
removed followed by one wash with PBS. A 0.25% trypsin solution was added and the 
cells were incubated at 37°C until they detached. Fresh medium was then added, the 
cells centrifuged and re-suspended to obtain the desired concentration and plated in a 
new dish.  
All cell lines were routinely screened for mycoplasma infection using the VectorGem 
Myco Detection kit (Vector). 
 
3.3.2 Freezing and thawing  
 
Logarithmically growing cells were trypsinized, harvested by medium addition and 
centrifuged as described above. The supernatant was then removed and the cells re-
suspended in normal culture medium containing 10% DMSO. The suspension was 
placed in appropriate 1.8 ml vials. Prepared cells were immediately placed in - 80°C 
and after some days moved to liquid nitrogen.  
Cells were quickly thawed at 37°C, and warm medium was added to dilute the DMSO. 
They were then centrifuged, re-suspended in fresh medium and immediately plated. 
 
3.4 DNA and RNA methods 
 
3.4.1 Measurement of the concentration of nucleic acids 
 
DNA or RNA concentration was measured by using 2 µl of the aqueous nucleotide 
solution and the Nanodrop spectrophotometer. The optical density (OD) of the nucleic 
acids was measured at 260 and 280 nm. A 260/280 OD ratio of ~1.8 indicates a 
relatively pure DNA and a ratio of ~2.0 is generally accepted as pure for RNA.  
A 50 µg/ml solution of double stranded DNA or a 40 µg/ml solution of single stranded 
RNA has an absorbance of 1.0 at 260 nm. Therefore the concentration is calculated by 
the software ND-1000 (version 3.1.2) as follows: 
DNA concentration (µg/ml) = (OD 260) x (dilution factor) x (50 µg DNA/ml)/(1 OD260 unit) 
RNA concentration (µg/ml) = (OD 260) x (dilution factor) x (40 µg RNA/ml)/(1 OD260 unit) 
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3.4.2 Agarose gel electrophoresis 
 
Dependent on the size of the fragments to be analysed, 0.8-1.5% agarose gels were 
used to separate DNA or RNA. The agarose was dissolved in 1X TAE buffer with the 
help of a microwave oven. When the solution was cool, a few µl of ethidium bromide 
were added before pouring the solution into the running chamber, already provided 
with a comb. As soon as the gel solidified, the comb was removed and the chamber 
was filled with sufficient amount of 1X TAE buffer to fill the wells and cover the gel. 
Finally, loading buffer was pipetted to an appropriate amount of DNA or RNA. The 
probes were loaded and a 60-80V current was applied to the gel, until they reached 
the desired separation. The bands were then visualized with UV light and a picture was 
taken. 
 
50X TAE for agarose gel  
Tris     2 M  
Acetic Acid     2 M 
EDTA pH8.0     50 mM 
 
6X Loading buffer for agarose gel 
Bromphenol blue    0.25% (w/v) FF  
Xylene cyanol    0.25% (w/v) 
Sucrose    40% (w/v) 
 
3.4.3 Whole RNA Cell Extraction  
 
Cells were grown to confluency on a 100 mm diameter Petri dish. They were washed 
twice with PBS before adding 6 ml Trizol. The cell lysate was collected in a fresh tube 
and incubated for five minutes at room temperature for complete disruption. After 
addition of 1.2 ml of chloroform, the tube was vigorously shaken for 15 seconds and 
then allowed to stand for two minutes in order to separate the organic from the 
inorganic phase. The solution was then centrifuged at 12000g, at 4°C for 15 minutes, 
so that the upper aqueous phase could be recovered and put in a fresh tube. To 
precipitate the nucleic acid, 750 µl isopropanol were added and the solution was 
incubated for 10 minutes at room temperature, followed by 10 minutes of 
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centrifugation at 12000g at 4°C. The supernatant was removed, and the RNA was 
washed with 75% ethanol by vortexing and centrifuging for five minutes at 7500g at 
4°C. The ethanol was then removed and the RNA was air dried, before re-dissolving it 
with 80µl of water. Finally, the solution was heated to 57°C for 10 minutes. 
The concentration of the RNA was measured and the purity was assessed by loading 
the probe on an agarose gel. 
 
3.4.4 cDNA synthesis 
 
For cDNA synthesis, Superscript II was used according to manufacturer’s instructions, 
and the reaction was performed in the buffer provided (5X First Strand Buffer). Briefly, 
a 20 µl reaction was set up for each RNA sample, starting from the master mix: 
10 mM dNTPs mix 1 µl  
150 ng random primers 1 µl 
2 µg total RNA x µl 
Sterile, distilled H2O up to 12 µl 
This mix was heated at 65°C for 5 minutes, quick chilled and briefly centrifuged to 
recover the whole solution. Then 4 µl 5X First Strand Buffer and 2 µl 0.1M DTT was 
added, and the mix incubated at 25°C for 2 minutes. After this incubation time, 1 µl 
Superscript was finally added to the reaction mixture, and gently pipetted up and down 
to ensure proper mixing. The tube was put in the thermo cycler with the following 
conditions: 
10 minutes 25°C 
50 minutes 42°C 
15 minutes 70°C 
To check the integrity of the cDNA, a control PCR reaction with HPRT primers was 
performed using 25 µl of cDNA from the first-strand reaction. The PCR product was 
then loaded on an agarose gel. 
 
5X First Strand Buffer  
250 mM Tris-HCl (pH 8.3 at room temperature),  
375 mM KCl,  
15 mM MgCl2 
 
3.4.5 PCR 
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If not otherwise stated, DreamTaq (Fermentas) was used. The reaction mixture was 
combined while keeping all the reagents and the tubes on ice. For each reaction, a 50 
µl master mix reaction was prepared, pipetting to the provided 10X buffer the following 
reagents: 
dNTPs 10 mM 1 µl 
Forward primer 0.2 µM 
Reverse primer 0.2 µM 
DNA or water 2 µl 
Finally, 0.4 µl of the DreamTaq enzyme was added, nuclease-free water was pipetted 
up to the desired volume and the samples were put into the thermocycler for the 
reaction (Table 2). This started with a pre-run (step 1), followed by a short heating that 
allowed the DNA strands to separate from each other (Tm = melting temperature). In 
step three the temperature drops and the primers can thus anneal to the single 
strands (Ta = annealing temperature). The reaction is then heated up again in step 
four to reach the optimal temperature for the DNA polymerase, allowing the synthesis 
of the new strand by extension of the primer (Ts = synthesis temperature). This 
sequence is then repeated for several cycles, until a final elongation at 72°C (Te = 
elongation temperature) concludes the reaction (step 5). 
 
Oligo/ 
reaction 
Step 1 Step 2 Step 3 Step4 Step 5 Cycles 
no. 
Tm1 time Tm2 time Ta time Ts time Te time 
huHPRT 95 2’ 95 1´ 61 30´´ 72 2` 
72 
5’ 30 
huASAP1 95 2´ 95 15´´ 70 30´´ 72 5` 5’ 30 
SLK 
cloning 
98 30´´ 98 10´´ 64 30´´ 72 2` 10’ 30 
 
Table	  2:	  Cycling	  conditions	  for	  the	  PCR	  reactions.	  All	  the	  tempreatures	  indicated	  are	  in	  °C	  
 
3.4.6 Isolation of DNA fragments from agarose gels 
 
The band of interest was cut out from the gel and weighed, and subsequently purified 
with the PeqGold Gel Extraction Kit from PeqLab according to the manufacturer’s 
instructions. The purified fragment was eluted with 30 µl water and the concentration 
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was measured with a Nanodrop spectrophotometer. The purity of the fragment was 
also assessed by loading it again on an agarose gel. 
 
3.4.7 Preparation of CaCl2 competent E. coli cells 
 
An E. coli culture at OD600 of 0.06 was added to 50 ml LB selective medium. When the 
bacteria reached the logarithmic phase of growth, cultures were centrifuged at 4,000 
rpm for 10 minutes at 4°C. The pellet obtained was then washed twice in 20 ml 0.1 M 
MgCl2. The clean pellet was resuspended in 2 ml 0.1 M CaCl2, before being incubated 
on ice for at least 2 hours. Sterile glycerol (ratio 1:1) was added, the competent cells 
aliquoted and frozen in liquid nitrogen. 
 
3.4.8 Isolation of plasmid DNA  
 
One vial containing 100 µl of competent XL1-Blue bacteria was thawed on ice for 15 
minutes. Then 20 ng of DNA was added and incubated with the bacteria for 30 
minutes. The bacteria were then heat shocked at 42°C for 90 seconds and then 
immediately chilled on ice for three minutes. SOC medium was then added to a final 
volume of 1 ml and the vial was put on a shaker at 37°C for one hour. Bacteria were 
then streaked on a selective agar plate containing ampicillin and incubated over night 
at 37°C. On the following day, several colonies were picked and allowed to grow over 
night in 1.5 ml selective LB medium at 37°C under constant shaking. The cell 
suspension was then centrifuged at 17000g for one minute, and 200 µl TELT buffer 
containing lysozyme were added, followed by vortexing in order to completely lyse the 
bacterial cells. The suspension was heated for three minutes at 96°C and quickly 
chilled on ice for five minutes. In order to clear the lysate, it was centrifuged for eight 
minutes at 17000g at room temperature, and the pellet was carefully discarded. To 
precipitate the DNA, 150 µl isopropanol was pipetted to the solution and centrifuged 
at 17000g for five minutes. The supernatant was discarded, and the pellet was 
washed twice with 70% ethanol. Finally the pellet was air dried and re-dissolved in 50 
µl ddH2O. The concentration was assessed by Nanodrop measurement. 
 
 
TELT buffer for plasmid mini preparation 
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Tris pH8    50 mM 
EDTA     62.5 mM 
Triton X-100 (TX-100)   0.4%  
LiCl     2.5 M 
Lysozyme    1 mg/ml 
 
Luria Bertani (LB) medium for bacteria growth (g/l)  
NaCl     5 
Yeast Extract    5 
Tryptone    10 
 
3.4.9 Digestion of DNA with restriction enzymes 
For restriction enzyme digestions, 1 µg of DNA was incubated with the appropriate 
buffer and 1 µl of enzyme(s) for one hour at 37°C. The reaction was then stopped by 
heat inactivation of the enzyme at 65°C for 20 minutes.  
 
3.4.10 Large-scale plasmid preparation 
Large-scale plasmid preparations were performed with the Quiagen Maxi kit following 
the manufacturer’s instructions. Briefly, a single colony from a freshly streaked 
selective agar plate was picked and inoculated into 3 ml of LB medium containing 
ampicillin. The bacteria were grown for ~8 hours and then this starter culture was 
diluted into 200 ml of selective medium using a vessel with a volume of at least four 
times greater than that of the medium. Again the bacteria were allowed to grow under 
constant shaking (~300 rpm) over night. The next day the cells were centrifuged and 
either stored at -20°C or immediately processed for plasmid isolation following the 
manufacturer’s protocol. 
  
3.4.11 RNA interference 
 
The corresponding company controls were used for each siRNA. The ratio nmol 
siRNA:µl Lipofectamine 2000 was always 0.1:5. For all oligonucleotides, the 
transfection was performed as follows. Cells were seeded to reach a confluence of 
~50% on the transfection day. Both the oligonucleotides and the Lipofectamine 
2000 were separately diluted in OptiMem according to the Lipofectamine 2000 
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protocol. In case of a co-transfection, the RNA amount was divided equally between 
the two sequences, in order to maintain a constant total amount of RNA. 
Briefly, the diluted Lipofectamine 2000 was incubated for five minutes at room 
temperature, and subsequently combined with the diluted oligonucleotides. The 
mixture was incubated for 20 minutes at room temperature, and finally added drop 
wise to the cells. These were maintained in medium containing FCS, but without 
antibiotics. The knock down was most efficient after 72 hours for all three siRNAs. 
The following silencing sequences and protocols have been used: 
Gene Name/company Sequence 5´- 3´ 
ASAP1 Stealth RNAi/ Invitrogen GACCAGAUCUCUGUCUCGGAGUUCA 
SLK Stealth RNAi/ Invitrogen UGUCCUUCUUCAAUUUCCGUAAGAU 
Nm23-H1 Silencer Validated 
siRNA/Ambion 
GGAACACUACGUUGACCUGtt 
 
3.4.12 DNA plasmid transfection 
 
For the transfection of plasmid DNA, Lipofectamine 2000 or Lipofectamine LTX were 
used, depending on the cell type and the application. The cells were plated to reach a 
density of ~90% on the day of transfection. For both cases, manufacturer’s 
instructions were followed for the preparation of the transfection mixture, and the cells 
were always kept in an antibiotic-free medium. Both DNA and Lipofectamine 2000 
were diluted in OptiMem. The ratios of DNA:Lipofectamine used were:  
− Lipofectamine LTX   1:3 
− Lipofectamine 2000  1:2.5 
In case of a co-transfection, the DNA amount was divided equally between the two 
plasmids, in order to maintain a constant total amount of DNA. The DNA solution was 
added drop wise to the cells. After 48 hours the transfection efficiency reached its 
maximum, and the cells were ready for subsequent analysis or experiments.  
 
3.4.13 Cloning of human Ste20-Like Kinase 
 
The cloning of human Ste20-like kinase was performed with the pcDNA™3.1⁄V5-His 
TOPO® TA kit (Life Science, Darmstadt). This kit allows the insertion of the expression 
sequence of the gene in frame with a polyhistidine tag, thus the resulting protein will 
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be a fusion protein. Total RNA from 293T cells was isolated, and cDNA was 
synthesized as previously described. Specific primers were designed and used to 
amplify the SLK sequence of the cDNA. For the PCR reaction, the proofreading 
polymerase Phusion (NEB) was used. A master mix was prepared by combining the 
provided 5X buffer with 1 µl each of 10 mM dNTPs, forward primer, reverse primer and 
the polymerase. Either 2 µl of cDNA or of water as a control were added, and finally 
nuclease-free water was added up to 50 µl for each reaction. The cycling conditions 
were as shown in Table 2. The PCR product was then loaded onto an agarose gel, and 
the band was excised and purified as previously described.  
For the cloning, the following reaction was set up: 
PCR product      4ul  
Salt solution (1.2 M NaCl; 0.06 M MgCl2)  1ul 
TOPO vector     1ul 
H2O      up to 6ul 
The mixture was incubated for 15 minutes at room temperature, before adding 2µl of 
the mixture to 50 µl of Top10 cells, previously thawed on ice. The bacteria were kept 
on ice for 15 minutes and then heat shocked for 30 seconds at 42°C. Then 250 µl 
SOC medium were added to the cells, which were kept at 37°C for one hour with 
shaking. Finally, 200 µl of bacteria suspension was plated on pre-warmed, selective 
LB-agar plates. The next day, several colonies were picked and inoculated with 1.5 ml 
selective LB and allowed to grow over night. The cloning was checked with a mini 
preparation of DNA and the resulting plasmid digested with an appropriate enzyme 
(XhoI) at 37°C for 90 minutes. The digestion with this enzyme of the plasmid 
containing the correct insert would result in two unique fragments of distinct molecular 
weight (8.5 kDa + 0.7 kDa). The fragments were loaded onto an agarose gel, and the 
colonies that contained the correct plasmid were inoculated for a maxi DNA 
preparation as previously described. This was checked again by digestion with the XhoI 
enzyme (Figure 22), before proceeding with the sequencing carried out by Eurofins 
MWG, Ebersberg. 
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Figure	   22:	   Control	   digestion	   of	   the	   His-­‐SLK	  
expression	  plasmid.	  The	  gel	  was	  photographed	  twice	  during	  the	  run	  (the	  picture	  on	  the	  right	  is	  a	  longer	  run)	  to	  better	  visualize	  the	  two	  fragments	  of	   8.5	   kDa	   and	   0.7	   kDa,	   respectively,	   that	   result	  form	   the	   digestion	   with	   XhoI	   of	   the	   His-­‐SLk	  expressing	  plasmid. 
 
 
3.5 Protein methods 
 
3.5.1 Preparation of protein samples for SDS-PAGE 
 
Protein samples were prepared as follows, unless otherwise indicated: 
Cells were kept on ice and washed twice with cold PBS. Approximately 100 µl cold lysis 
buffer/106 cells were added and the cells were detached from the plate by scraping. 
The lysate was collected in a fresh tube and sheared five times through a 27G needle, 
before centrifuging it for 15 minutes at 4°C at 12000g. The cleared lysate was then 
either stored at -20°C or immediately used for subsequent analysis. 
 
Lysis buffer 
Tris pH 7.5     50 mM 
NaCl      150 mM 
EDTA      5 mM 
TX-100      1% 
PMSF      1 mM 
Protease inhibitor cocktail (Roche)  1x dilution 
 
3.5.2 Protein concentration determination 
 
The protein concentration of cell lysates was assessed with a commercially available 
bicinchoninic acid assay, using known concentrations of bovine serum albumin for the 
calibration curve. A 1:5 dilution of the lysate was used for the colorimetric reaction that 
was performed in a flat bottom 96 well plate. The color development is proportional to 
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the amount of protein present in the solution, and was measured at 595nm with an 
ELISA reader. The concentration was then calculated with the Ascent software, 
according to the calibration curve. 
 
3.5.3 SDS-polyacrylamide gel electrophoresis (PAGE) 
 
SDS-PAGE gels were prepared as follows. The percentage of acrylamide for the 
resolving gel was selected according to the size of the proteins to be separated. The 
components of the solution were carefully mixed, avoiding the formation of air 
bubbles. APS and TEMED were added only at the end, as they start the polymerization 
reaction. The resolving gel solution was poured first, and the surface was immediately 
covered with a thin layer of water-saturated butanol. When the gel was polymerized, 
the butanol was removed and the gel was briefly washed with water. The comb was 
then put into place and the stacking gel solution was carefully poured and allowed to 
polymerize. When ready, the comb was carefully removed and the resulting wells 
delicately washed with running buffer. The gel was then taken out of the casting stand 
and inserted into a clamping frame together with another gel or with the provided 
buffer dam to create a leak-proof seal. The electrode assembly was inserted into the 
tank filled with running buffer and the protein samples were loaded. 
These were prepared by adding 4X loading buffer and boiling them at 95°C for five 
minutes. The samples were briefly spun down and loaded onto the SDS-PAGE gel. Gels 
were run with constant Amperes and 60V until the protein front reached the resolving 
gel, then a voltage of 80V was applied. The gels were run until the blue dye reached 
the lower edge of the resolving gel. They were then removed from the apparatus and 
soaked in transfer buffer for equilibration. 
 
Buffers and solutions 
 
4X Loading Buffer 
Tris-HCl pH 6.8    0.1 M 
SDS         8% 
Glycerol     40% 
Bromophenol Blue   0.02% 
DTT     0.1 M 
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Solutions for acrylamide gel preparation: 
 Resolving Gel Stacking Gel 
Tris pH8.8 0.375 M - 
Tris pH6.8 - 0.125 M 
acrylamide 8-12% 3% 
Water  up to volume 
SDS 0.01% 
APS 10% 0.01% 
TEMED 0.001% 
  
1x Running buffer 
Glycine     25 mM 
Tris      192 mM 
SDS     0.1% 
 
3.5.4 Coomassie stain 
 
When needed, SDS-PAGE gels were soaked in the staining solution and allowed to 
stain overnight under shaking at room temperature. The day after, the gel was de-
stained by doing several one-hour washes with the de-staining solution until clear. 
Finally, the gel was put on a filter paper in the Gel Dryer for three hours at 60°C. 
 
Staining solution  
Coomassie brilliant blue   2% 
Methanol    40% 
Glacial acetic acid   5% 
Water up to volume 
 
De-staining solution 
Methanol    40% 
Glacial acetic acid   5% 
Water up to volume 
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3.5.5 Western Blot 
  
SDS-PAGE gels were soaked in transfer buffer before assembly of the blot. An 
appropriate size of PVDF membrane was cut and prepared for the blotting, which was 
carried out according to manufacturer’s instructions. Briefly, the membrane was 
soaked for a few seconds in methanol until translucent, and then wetted in water for 2 
minutes. Finally, it was soaked in the transfer buffer for equilibration for at least 5 
minutes. 
The stack for the blotting was prepared as follows, starting from the cathode side: one 
sponge pad, two layers of filter paper, the gel, the membrane, two filter paper sheets 
and another sponge pad. Attention was paid not to allow air bubbles to form between 
the layers. The gel was electro-blotted onto the membrane with continuous stirring of 
the transfer buffer either for 2 hours at 100V, or overnight at 30V. 
At the end of the blotting, the gel was discarded and membrane was briefly rinsed with 
washing buffer and air dried, before being incubated with blocking buffer for one hour 
at room temperature. The incubation with the primary antibody, diluted in the blocking 
buffer, was performed either at room temperature for two hours or over night at 4°C. 
The appropriate secondary antibody was incubated with the membrane for one hour, 
following a five-minute wash with washing buffer. Finally, the membrane was rinsed 
three times before proceeding to the chemiluminescent reaction. For this process the 
ECL detection reagent was prepared according to manufacturer’s instruction and 
pipetted onto the membrane. After one minute incubation the membrane was exposed 
to several X-ray films for between 5 seconds and up to 30 minutes, depending on the 
strength of the signal. In case of a weak or even absent signal the membrane was 
shortly rinsed and the procedure was repeated with another detection reagent, 
AceGlow, which ensured a higher sensibility.  
If proteins of the same or similar molecular weight were to be visualized onto the same 
membrane, this was subjected to a stripping procedure. The membrane was soaked 
into a stripping solution at 42°C for 30 minutes, and then washed three times for ten 
minutes with the washing buffer. The membrane was then incubated again with the 
blocking buffer for one hour 
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Buffers and Solutions 
 
1x Transfer buffer 
Glycine     25 mM     
Tris     192 mM 
SDS     0.1% 
Methanol    15%-20% according to protein size 
 
 
Tr is-buffered sal ine (TBS) 10X 
Tris HCl, pH 7.4     500 mM  
NaCl     1.5 M 
 
Washing buffer 
TBS     1X 
Tween     0.05% 
 
Blocking buffer 
Bovine serum albumin   1% 
TBS     1X 
Tween     0.05% 
 
Str ipping solution 
SDS      2% 
β -mercaptoethanol   0.7% 
Tris-HCl pH 6.8    62.5 µM 
 
3.5.6 Co-immunoprecipitation 
 
293T cells were transfected with a Flag-tagged ASAP1 expression plasmid alone or in 
combination with Nm23-H1 or h-prune as described in 3.5.13. After 48 hours post 
transfection cells were kept on ice and washed twice with cold PBS. Approximately 
100 µl cold lysis buffer/106 cells was added and the cells were detached from the 
plate by scraping. The lysate was collected in a fresh tube and sonified twice for 30 
seconds, with a five minute break in between. In order to get rid of the cellular debris, 
the lysate was then centrifuged twice for 15 minutes at 4°C at 12000g. The cleared 
lysate was then either stored at -20°C or immediately used for subsequent analysis. 
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Aliquots (400 µg) of cleared cell lysate were combined with 50 µl of protein G+ 
agarose resin and were incubated with rotation for two hours at 4°C. The lysate was 
then centrifuged for five minutes at 12000g at 4°C, then the supernatant was 
recovered and put in a fresh tube. The procedure was repeated a second time, in order 
to get rid of the non-specific binding to the resin. Flag M2 antibody (6 µg), the 
corresponding isotype antibody control, or no antibody were added to the cleared 
lysate, and incubated again with rotation for two hours at 4°C. Finally, 50 µl of protein 
G+ agarose resin were pipetted to each probe and the co-immunoprecipitation 
occurred over night, always under rotation, at 4°C. On the following day the beads 
were washed with the washing buffer by centrifuging them three times at 17000g for 
three minutes. An appropriate amount of 4X loading buffer was added and the beads 
were boiled at 95°C for five minutes. The suspension was quickly centrifuged and the 
supernatant loaded onto an SDS-PAGE gel. 
 
Co-immunoprecipitat ion lysis buffer:  
HEPES pH7.4     25 mM 
NaCl      150 mM 
MgCl2      10 mM 
Lubrol      1% 
Na3VO4      10 mM 
PMSF      1 mM 
Protease inhibitor cocktail (Roche)  1x dilution 
 
Washing buffer:  
HEPES pH7.4     25 mM 
NaCl      150 mM 
MgCl2      10 mM 
 
3.6 SH3 Domain Array  
 
The array used for this assay was purchased at Panomics/Affymetrix, (Santa Clara, 
USA), and is composed of two identical PVDF membranes on which specific SH3 
recombinant proteins have been spotted. These proteins consist of the purified 
recombinant conserved binding site of the individual SH3 domain proteins, and are 
different among the four arrays available. We used the SH3TM Domain Array I, which 
contains the protein visualized in Figure 23. If the membrane is incubated with a cell 
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lysate containing Flag-tagged transfected ASAP1, this will selectively bind to its SH3 
interaction partners. By subsequent incubation of the membrane with the anti-Flag 
antibody, the interaction and its strength will be visible as a spot in correspondence to 
the putative SH3 binding protein. 
 
Figure	  23:	  Schematic	  diagram	  of	  the	  SH3	  domain	  array	  I.	  All	  recombinant	  proteins	  are	  spotted	  in	  double.	  	  
 
On day one, 293T cells were seeded in 15 cm diameter Petri dishes. The day after, the 
confluent cells were transfected with the indicated plasmids as described in 3.5.13 
After 48h, the dishes were put on ice, then the cells were briefly rinsed and harvested 
with 5 mM EDTA-PBS. They were then counted, and lysed in the Resuspension Buffer 
containing proteinase inhibitors (approximately 1 ml buffer/106 cells). The lysate was 
sonified twice and finally centrifuged. The protein content was assessed, and the 
lysate was diluted with Resuspension Buffer to a final concentration of 1 mg/ml, then 
frozen. The transfection was checked by means of Western Blot.  
For the assay, the lysates were thawed on ice and the SH3 domain array membranes 
containing the recombinant proteins was prepared following the manufacturer’s 
instructions. Each membrane was then incubated for 90 minutes with the lysate to 
enable the possible binding of ASAP1 with the SH3 domain-bearing proteins. This step 
was followed by three washes of ten minutes with the washing buffer. The membrane 
was incubated overnight with the ASAP1 antibody diluted in the washing buffer. 
On the following day, the membrane was washed three times for ten minutes, and 
then incubated with the appropriate secondary antibody for 30 minutes, followed by 
three ten-minute washes. For the detection, equal amounts of Detection Buffer A and 
B were combined and gently pipetted onto the membrane. The array was then exposed 
on X-ray films for various times. 
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Buffers provided by the kit :  
 
1X Resuspension Buffer 
1X Blocking Buffer 
10X Washing Buffer 
Detection Buffer A 
Detection Buffer B 
 
3.7 Recombinant Cortactin Dot Blot 
 
PVDF membrane was cut to a ca. 10 cm x 3 cm rectangle, pre-wetted with 100% 
methanol and washed twice with the Western blot washing buffer. It was then allowed 
to semi-dry. Recombinant cortactin identical to the one used for the SH3 array was 
provided by Panomics as a 1 µg/µl solution. For each dot, 1 µl of a 1:10 dilution was 
spotted onto the membrane and allowed to absorb. The membrane was then 
incubated for one hour shaking at room temperature in washing buffer containing 1% 
BSA. The lysate-binding assay then followed the same protocol as for the SH3 domain 
array assay described above (Section 7). As a negative control, the membrane was 
incubated with the secondary antibody only. Incubation with an anti-GST antibody that 
binds to the recombinant cortactin spotted on the membrane served as a positive 
control. 
 
3.8 Production of the 7B12 anti-ASAP Antibody 
 
The 7B12 antibody-producing hybridoma cells were previously established in the lab 
by immunizing Balb/C-mice with a recombinant ASAP1 protein (Müller et al., 2010). 
Hybridoma cells were grown in 150 mm diameter plates with 50 ml medium until they 
died. The conditioned medium was then collected and stored at -20°C. A total amount 
of two litres of conditioned medium was collected. To remove cellular debris, the 
medium was centrifuged for 10 minutes at 4°C at 4000 rpm. Solid ammonium 
sulphate was added with slow stirring to obtain a final concentration of 50% (313 g/l). 
This solution was left gently stirring over night at 4°C, and finally centrifuged for 10 
minutes at 4°C at 4000 rpm. The supernatant was discarded and the resulting pellet 
was re-suspended in 20 ml/l buffer A. This solution was dialysed for 24 hours against 
buffer A, changing the dialysis buffer three times. The dialyzed solution was 
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centrifuged for 10 minutes at 10000 rpm and Protein G+ agarose beads were added 
to the supernatant to a final amount of 3 ml 50% slurry/l medium. This suspension 
was then incubated for two hours with rotation at 4°C, and finally centrifuged at 3000 
rpm to remove unbound protein. The beads were washed four times with buffer A and 
transferred into a BioRad poly-prep 1.5 ml column until the gel was packed and the 
excess fluid was drained off. 
The elution of the antibodies was carried out using 100 mM glycine pH 2.5 (5x0.5 ml 
fractions neutralized with 50 µl 1M Tris pH 9.6) followed by 100 mM NaHCO3 pH 10.8 
(4x0.4 ml fractions neutralized with 87 µl 100 mM Na3C6H5O7  pH 5.0).  
The concentration of each fraction was measured with the Nanodrop 
spectrophotometer. A microliter of sample was pipetted onto the optical surface of the 
instrument, and by closing the apparatus a sample column is formed. Using the 
spectral measurement at 280nm the instrument provides via its software the 
quantification of the sample. The formula applied was as follows: 
1.35 A280 units of antibody = 1 mg/ml 
The most concentrated fractions were pooled together and dialyzed against PBS over 
night. The antibody concentration was measured again, and the antibody was finally 
checked via SDS-PAGE and Coomassie stain. The aliquots were stored at -20°C. 
 
Buffer A 
NaHPO4 pH7.0  20 mM 
NaCl   150 mM 
 
Buffer B 
Glycine pH2.5  100 mM 
Tris pH9.6  1 M 
NaHCO3 pH10.8  100 mM 
Na3C6H5O7 pH5.0 100 mM 
 
3.9 Fast protein liquid chromatography (FPLC) 
 
For the FPLC studies, a Superose™ 10/300 GL Column (GE) was used, which is 30 cm 
long and has a diameter of 1 cm. The column was prepared following the 
manufacturer’s instructions. 
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Technical details of the separation strategy: 
Loaded volume 200 µl 
Flow rate 0.5 ml/second 
Gradient no 
Fraction size 250 µl 
Start collecting fractions 10 ml 
Stop collecting fraction 25 ml 
 
For the separation, MDA MB 231 cells were harvested with 5 mM EDTA in PBS and 
counted. Approximately 75 µl lysis buffer/107 cells were used. The lysate was sheared 
five times through a 27G needle and centrifuged at 12000 g for 15 minutes. The 
protein content was assessed, and the separation performed only if the protein 
concentration was at least 10 µg/µl, in order to load at least 2mg total protein onto 
the column. The sample was always re-centrifuged before applying to the column in 
order to avoid air bubbles. 
Fractions were collected in clean tubes and immediately put on ice. To 60 µl of each 
fraction, 20 µl of 4X loading buffer (see 3.5.3) were added. Samples were heated to 
95°C for five minutes and loaded onto an appropriately-sized SDS-PAGE gel. On each 
gel, 40 µg of non-fractionated lysate were also loaded as a control. 
 
Equil ibration Buffer  
Tris HCl pH 7.5    50 mM 
KCl     100 mM 
 
Elution Buffer 
HEPES pH7.0    25 mM 
NaCl     125 mM 
NaVO4     10 mM 
Lubrol     1% 
PMSF     1 mM 
Protease inhibitors cocktail (Roche) 1x dilution 
 
3.10 Isolation of Primary Mouse Embryonic Fibroblasts (MEFs) 
 
The mice used for the isolation and purification of embryonic fibroblasts were ASAP1 
knock out (RRS873), purchased from BayGenomics. The animals were kept in the ITG - 
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Institute for Toxicology and Genetics, part of the KIT - Karlsruhe Institute of Technology 
- animal facility under full specific pathogens free (SPF) conditions. The mice were bred 
onto a FVB background and kindly genotyped by Gitta Flaig, CBTM. The local 
authorities approved all studies performed with laboratory animals. 
Pregnant female mice at F5 were sacrificed on embryonic day 13.5 by cervical 
dislocation. In a sterile hood the abdomen was swabbed with 70% ethanol and opened 
to expose the uterine horns. These were immediately excised and placed on a clean, 
PBS-filled Petri dish that was kept on ice during the whole isolation procedure. Each 
embryo was dissected from the placenta and was put on a clean Petri dish, avoiding 
contamination with maternal tissues. The yolk sack was removed and kept for 
subsequent genotyping. Head, heart, liver and spleen were removed from the embryo, 
and the remaining tissue was cut into smaller pieces. These were placed in cold PBS, 
washed once and allowed to settle on ice. The PBS was then removed, and 2 ml of ice 
cold 0.25% trypsin-EDTA was added. The digestion of the tissues occurred over night 
on ice. The following day, the trypsin was carefully removed and the tissue was 
incubated at 37°C for 20 minutes. After this time, 5 ml of warm media was used to 
gently pipette the lysed tissue up and down, in order to obtain a single-cell suspension. 
This suspension was finally plated in a T175 flask, together with 30 ml medium. On 
the following day, the medium was aspirated to remove cell debris and non-fibroblast 
cells. The MEFs were allowed to grow until they reached confluence and were then 
frozen in several aliquots in FCS + 10% DMSO. 
 
3.11 FACS sorting 
 
Due to the low transfection efficiency of the MEFs these cells had to be FACS sorted by 
co-transfecting the plasmid of interest with a GFP-expression construct. Freshly 
thawed, passage one MEFS were plated in 6 cm diameter dishes. On the next day they 
were re-seeded into 10 cm diameter plates, to be ~70% confluent on the day of 
transfection (day 3). For the co-transfection, 21 µl Lipofectamine LTX were mixed with 
7 µg of DNA (3.5 µg for each plasmid) diluted in 5.6 ml OptiMem. The solution was 
vortexed for few seconds and incubated for 30 minutes. Meanwhile the cells were 
washed and the medium replaced with antibiotic-free medium. Finally, the transfection 
mixture was added drop wise to the cells, and the plate was gently rocked to evenly 
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distribute the solution. On the next day, cells were re-plated in 15 cm diameter plates, 
and the antibiotic solution containing penicillin and streptomycin was again added to 
the medium. After 48 hours of transfection the cells were trypsinized, washed once 
with PBS, re-suspended in 200 µl cold PBS containing 2% FCS, and kept on ice for the 
whole sorting procedure (~2 hours), which was kindly carried out by Melanie Grassl 
(CBTM – Mannheim). At the end the GFP-positive sorted cells were centrifuged, re-
suspended in warm medium and plated in 48-well plates. 
 
3.12 Motility Assay  
 
3.12.1 Motility assay with MDA MB 231 cells 
 
Aliquots of 0.15 x 106 cells were seeded in 35 mm diameter dishes and transfected as 
described above. Four hours post-transfection, cells were trypsinized, harvested and 
re-plated 1:10 in the same dishes. The remaining cells were used for the motility assay 
and seeded a 6-well plate, which were previously prepared by putting three sterile 
silicon inserts into each plate (Figure 24). These were obtained by removing the silicon 
grid of an 8-well Lab-Tek™ Chamber Slide™ and by cutting it to the appropriate size. 
After soaking them in ethanol for few minutes, the inserts were air dried and sterilized 
with UV light for one hour before every assay. 
 
 
Figure	  24:	  The	  6-­‐well	  plates	  used	  for	  the	  motility	  assays	  were	  prepared	  by	  adhering	  three	  silicon	  inserts	  to	  the	  bottom	  of	  the	  well	  prior	  to	  seeding	  the	  cells.	  
	  
After 48 hours of transfection the assay was 
started. The cells in the 35 mm dishes were lysed in order to assess the transfection 
efficiency using western blotting. In parallel, the silicon inserts in the 6-well plates 
were carefully removed and the cells were washed twice with PBS. Pictures were taken 
immediately (t=0) and at later time points (24h, 32h and 48h). At t=24 the medium 
was changed. At the end of the assay, the cells in the 6-well plates were also lysed to 
check transfection efficiency at this time point. For each monolayer wound, five 
pictures were taken and in each picture the distance between the edges of the cell 
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monolayer was measured at four different points (Figure 25). The distance between 
the cell fronts was analysed with ImageJ software. 
 
Figure	   25:	   This	   figure	   depicts	   how	   the	   motility	   assays	  were	   analyzed.	   On	   the	   left	   it	   is	   shown	   how	   the	   five	  pictures	   were	   taken	   for	   each	   insert.	   The	   right	   figure	  represents	   one	   of	   these	   pictures	   and	   the	   dotted	   lines	  correspond	   to	   the	  measurements	   taken,	   namely	   four	   for	  each	  picture. 
 
3.12.2 Motility assay with MEFs  
 
For each experiment, three wild-type and three ASAP1 knock out MEFs were used. 
0.05 x 106 cells per well were seeded in a 12-well plate. The plates were prepared with 
three silicon inserts per well as described above, but the inserts were shorter in order 
to fit into the well. On the following day, the inserts were carefully removed and the 
wells washed twice with PBS. Pictures were taken at t=0, 8 and 24 hours. To analyze 
the whole insert, it was divided in two pictures, each of which was measured at four 
points (Figure 26). The distance between the cells fronts was analysed with ImageJ 
software. 
 
Figure	   26:	   To	   analyze	   the	   motility	   of	   the	   MEFs	   the	  silicon	   inserts	   used	   were	   shorter	   and	   thus	   just	   two	  pictures	   were	   needed	   to	   take	   the	   whole	   area.	   For	  each	  picture	  the	  distance	  of	  the	  cells	  was	  measured	  at	  four	  different	  points	  of	  the	  cell	  front.	  	  	  
3.13 EGF recycling assay 
 
One day prior to transfection, 1.4 x 106 MDA MB 231 cells were seeded onto four 10 
cm diameter Petri dishes in antibiotic-free medium. Cells were transfected either with 
600 pmol of ASAP1-specific siRNA or with the appropriate control using Lipofectamine 
2000. The siRNA and the transfection reagent were diluted in OptiMem and prepared 
according to manufacturer’s protocol. 
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For concomitant Nm23-H1 knock down, the medium was changed after 4 hours and 
the cells were transfected with Nm23-H1 specific siRNA, or with the appropriate 
scrambled control. For concomitant Nm23-H1 or h-prune over expression, the 
following day cells were transfected after a medium change with the corresponding 
plasmids, or with empty vector as a control. In all cases, the day after the second 
transfection the cells were trypsinized. The cells were split 1:10 into one 35 mm Petri 
dish and subsequently used to control transfection efficiency. The remaining cells were 
plated onto one 15 cm Petri dish, and used for the EGFR recycling assay 72 hours 
after ASAP1 siRNA transfection. 
For the EGFR recycling assay, the cells were starved with serum-free medium for two 
hours at 37°C. They were then harvested with 5 mM EDTA-PBS, re-suspended in 3.6 
ml serum-free medium and stored on ice. For each assay condition (no EGF control, no 
internalization and 30 minutes internalization) four cell aliquots of 300µl each were 
used for technical replicates. The “no EGF” control samples were pipetted into clean 
tubes and kept on ice. The remaining cells were incubated with fluorescent EGF (Alexa 
Fluor® 488 EGF complex, Life Technologies, Darmstadt) at a final concentration of 1 
µg/ml for five minutes on ice. The cells were then centrifuged at 4°C and washed 
once with cold serum free medium. The “no internalization” sample was immediately 
stripped with Stripping buffer for five minutes. The other cells received pre-warmed, 
serum free medium, and were kept in the incubator for 30 minutes, before being 
stripped with Stripping buffer. The “no EGF” control cells were also stripped, and all 
samples were finally fixed with 37% buffered formalin. The cells were then subjected 
to FACS analysis and the fluorescence levels were assessed. 
 
Stripping buffer (in H2O) 
NaCl   0.5 M 
Acetic acid  0.2 M 
 
3.14 Cell staining 
 
To visualize the cells that received the fluorescent EGF, after the FACS sort additional 
steps were done. The excess cells not used for the FACS were spotted onto clean 
slides (Superfrost plus, Thermo Fisher Scientific, Schwerte) and allowed to adhere by 
air-drying. The cells were then shortly rinsed with PBS and incubated for 30 minutes 
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with a 2 µg/ml solution of tetramethylrhodamine wheat germ agglutinin conjugate (Life 
Technologies, Darmstadt), that specifically stains the membrane of the cells. Following 
this steps the cells were counterstained with 0.5 µg/ml DAPI (4',6-diamidino-2-
phenylindole) (Life Technologies, Darmstadt) for 10 minutes, before mounting a 
coverslip with an aqueous mounting medium (Fluoromount G - Southern Biotech). 
 
3.15 Statistical analysis 
 
For all experiments, statistical significance was calculated using a two-tailed student t-
test. A p value of less than 0.05 was considered significant. In all the graphs where a 
statistical analysis is showed, the following symbols were used: 
 
*  = p≤0.05 
** = p≤0.01 
***  = p≤0.001  
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4. RESULTS 
 
4.1 Role of ASAP1 in EGFR uptake and recycl ing 
 
4.1.1 Establishment of a FACS-based EGF internalization assay  
ASAP1 is able to bind and bend the plasma membrane via its BAR domain, thereby 
regulating the vesicle trafficking involved in receptor internalization and endosome 
recycling. Importantly, ASAP1 has been shown to induce tubular structures in vivo that 
contain the epidermal growth factor receptor (EGFR), and is thought to play a role in 
the internalization of this receptor (Nie et al., 2006). Overexpression of ASAP1 
increases the recycling of EGFR in CHO cells  (Kowanetz et al., 2004). ASAP1 has also 
been implicated in regulating the signalling of EGFR (see Introduction). The signalling 
pathways of the EGFR are known to promote growth and motility in vitro (Boulay et al., 
2008), as well as metastasis formation in vivo. I therefore hypothesized that 
internalization and recycling of the EGF-EGFR complex by ASAP1 might contribute to 
the metastasis-promoting activity of ASAP1. To determine if this is the case, I 
established a quantitative assay to measure the amount of internalized EGF-receptor 
complex in highly metastatic human breast cancer MDA MB 231 cells, and 
investigated the influence of ASAP1 and its binding partners on this activity.  
The assay I designed took advantage of the uptake of fluorescein-coupled EGF as a 
measure of the internalization activity of ASAP1 (Nie et al., 2006). To date, uptake in 
the published literature has only been assessed in a non-quantitative manner using 
microscopy. I therefore set out to develop an assay that used FACS measurement to 
quantify EGF uptake as a measure of EGFR recycling (Figure 27). In this assay, serum-
starved cells are harvested with PBS-EDTA to avoid cleavage of surface receptors, and 
cooled on ice to stop receptor internalization. The cells are then incubated with 
fluorescein-labelled EGF. Unbound EGF is subsequently washed away. The cells are 
then immediately processed, or incubated at 37°C for 30 minutes to allow 
internalization to occur. An acid stripping step before the fixation of the cells and 
subsequent FACS analysis allows cell surface-bound EGF to be removed, leaving 
fluorescent signal only from internalized EGF. The detailed protocol is outlined in  
“Materials and Methods”.  
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Figure	  27:	  Flow	  chart	  depicting	  the	  steps	  of	  the	  assay.	  The	  serum-­‐starved	  MDA	  MB	  231	  were	  gently	  collected	  with	  PBS-­‐EDTA,	  put	  on	   ice	  and	   incubated	  or	  not	  (“no	  EGF”)	  with	   the	   fluorescent	  EGF.	  Each	  treatment	   consisted	   of	   four	   technical	   replicates.	   The	   treated	   cells	   were	   then	   either	   immediately	  processed	   (“no	   internalization”),	   or	   let	   internalize	   the	   growth	   factor	   for	   30	  minutes	   at	   37°C,	   before	  being	  processed	  for	  the	  FACS	  analysis.	  
 
4.1.1.2 Time of EGF internalization 
First I performed several experiments to identify the optimal time for maximal 
internalization at 37°C of the fluorescein-labelled EGF. For this purpose I incubated 
MDA MB 231 cells with or without EGF for five minutes on ice, then immediately fixed 
them (“no internalization”), or allowed them to internalize the EGF for five or 30 
minutes at 37°C. The FACS analysis revealed that maintaining the cells at 37°C for a 
longer time (30 minutes) increased the fluorescence of the cells that received EGF, but 
not of the control ones (Figure 28). These and other results demonstrate the kinetics 
of the uptake of the growth factor, confirm the specificity of the fluorescence signal in 
the FACS analysis, and show that 30 minutes represents the optimal time at 37°C for 
EGF uptake following loading of the cells on ice. 
 
4.1.1.3 Optimization of the stripping procedure  
 
To further develop the EGF uptake assay, I implemented and optimized the stripping 
procedure as described in Lua and Low (Lua and Low, 2005) to be sure that I would 
only analyse receptor-bound and internalized EGF. Specifically, before fixing the EGF-
treated MDA MB 231 cells for the FACS analysis, I treated them with an acidic 
stripping buffer. I tested its efficiency using FACS analysis, and cross-verified this 
analysis by visualization with a fluorescence microscope. The serum-starved cells were 
kept in suspension on ice and were given the EGF for five minutes, before incubating 
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them at 37°C for five, ten or 30 minutes. After this time, the cells were “stripped” and 
fixed, or only fixed for the FACS analysis. 
 
Figure	  28:	  MDA	  MB	  231	  cells	  were	  treated	  or	  not	  treated	  with	  the	  fluorescent	  EGF	  as	  indicated,	  then	  either	   immediately	  processed	  (“no	   internalization”)	  or	  put	  at	  37°C	   for	   five	  or	  30	  minutes.	  The	  peaks	  indicate	  the	  mean	  fluorescent	  intensity	  of	  the	  cells,	  which	  clearly	  increases	  with	  the	  time	  in	  the	  treated	  cells,	  but	  not	  in	  the	  untreated	  ones,	  showing	  the	  specificity	  of	  the	  signal.	  	  
The analysis showed that immediately after EGF incubation, around 50% of the 
fluorescent signal is removed by the stripping treatment, and thus represents 
unspecifically bound growth factor (Figure 29A). The efficiency of the stripping was not 
100%, perhaps suggesting that even on ice, receptor internalization still occurs to 
some extent. After 30 minutes at 37°C, almost all EGF was internalized, as virtually no 
difference in fluorescence intensity between stripped and the non-stripped cells was 
observed (Figure 29A).  
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A 
The interpretation of the FACS analysis was confirmed using fluorescence microscopy 
(Figure 29B and C). The accumulation of internalized EGF-EGFR complex in 
intracellular vesicles is clearly visible at the 30 minute time-point. 
 
	  
	  
Figure	  29.	   Effect	  of	   the	   stripping	   treatment	  on	   the	   fluorescence	   signal	   in	   cells	   incubated	  with	  
fluorescein-­‐labelled	  EGF.	  MDA	  MB	  231	   cells	  were	   incubated	   for	   five	  minutes	  with	   the	   fluorescein-­‐
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coupled	  EGF,	  washed,	   then	  allowed	   to	   internalize	   the	   receptor	  at	  37°C	   for	   the	   times	   indicated.	  They	  were	  then	  immediately	  fixed,	  or	  stripped	  and	  fixed	  before	  analysing	  them	  by	  either	  FACS	  analysis	  (A)	  or	  microscopy	  (B	  and	  C).	  A.	  The	  mean	  fluorescence	  intensity	  as	  measured	  by	  FACS	  analysis	  is	  plotted	  against	  the	  time	  the	  EGF-­‐treated	  cells	  were	  incubated	  at	  37°C.	  B.	  Fluorescence	  microscopy	  images	  of	  representative	  cells	   incubated	   for	  up	  to	  10	  minutes	  at	  37°C	  after	   treatment	  with	   fluorescein-­‐labelled	  EGF	  on	  ice	  (no	  internalization).	  Cells	  were	  fixed	  either	  with	  or	  without	  stripping	  as	  indicated.	  A	  clear	  accumulation	  of	  EGF	  (green)	   is	  visible	  on	  the	  membrane	  (red)	  of	   the	  non-­‐stripped	  cells	  compared	  to	  the	  stripped	  ones.	  C.	  Fluorescence	  microscopy	  images	  of	  cells	   incubated	  for	  30	  minutes	  at	  37°C	  after	  treatment	   with	   fluorescein-­‐labelled	   EGF	   on	   ice	   (no	   internalization).	   Cells	   were	   fixed	   either	   with	   or	  without	   stripping	   as	   indicated.	   The	   arrows	   indicate	   the	   efficiency	   of	   the	   stripping	   in	   the	   “no	  internalization”	  cells.	  
 
4.1.1.4 EGF incubation time 
Another parameter that needed to be optimized was the incubation time of the EGF 
with the cells on ice prior to the internalization at 37°C. For this purpose, I kept the 
cells in suspension with the fluorescent EGF on ice for five, 30 and 60 minutes. Then I 
washed them and either processed them immediately (stripping and fixation), or 
allowed them to internalize the receptor at 37°C for five or 30 minutes, always 
followed by stripping and fixation. The binding of the EGF to the cells was very fast: the 
fluorescence signal did not show any difference whether the cells were incubated with 
the EGF for five, 30 or 60 minutes (Figure 30).  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure	  30:	  The	  graph	  shows	  the	  mean	  fluorescence	  intensity	  of	  the	  cells	  that	  were	  incubated	  with	  the	  EGF	  for	  five	  (white),	  30	  (blue)	  or	  60	  (green)	  minutes	  on	  ice.	  Each	  sample	  was	  allowed	  to	  internalize	  it	  at	  37°C	  for	  five	  or	  30	  minutes,	  or	  not	  at	  all.	  The	  fluorescence	  intensity	  was	  measured	  via	  FACS.	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This experiment suggested that incubating the cells on ice with EGF for longer times 
only slightly affects the final fluorescence intensity, whereas the duration of the 
internalization at 37°C is the main determinant of the increase in EGF signal intensity. 
Therefore for further experiments I chose to keep the cells for five minutes on ice 
before washing the unbound EGF away and proceeding with the internalization.  
 
4.1.1.5 EGF concentration 
Finally I needed to optimize the concentration of EGF to be given to the cells. For this 
experiment I incubated the cells for five minutes on ice with three different 
concentrations of EGF, before leaving them for five minutes at 37°C for the 
internalization. Although maximal signal was already obtained with 0,5 µg/ml 
fluorescein-labelled EGF, I decided to use a concentration of 1 µg/ml to ensure 
reliable saturation of the cell-surface EGFR (Figure 31). 
 
Figure	  31:	  To	  identify	  the	  optimal	  concentration	  of	  EGF	  the	  cells	  were	  all	  treated	  equally	  (five	  minutes	  of	   incubation	   on	   ice	   followed	  by	   five	  minutes	   internalization	   at	   37°C),	   but	  were	   given	  different	   EGF	  final	  concentrations,	  as	   indicated.	  This	  graph	  indicates	  that	  the	  fluorescence	  intensity	  is	  proportional	  to	  the	  EGF	  concentration.	  	  
 
4.1.2 ASAP1 knock down increases EGF fluorescent signal 
 
Having established an assay for the measurement of the internalization of fluorescent 
EGF into the MDA MB 231 cells, I wanted to confirm a role for ASAP1 in EGF uptake. 
For this purpose I treated the cells with a specific siRNA for ASAP1, as well as with the 
appropriate scrambled siRNA control, and performed the internalization assay. The 
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knock down of ASAP1 resulted in a statistically significant increase in the fluorescence 
intensity compared to the control, even in the cells that were kept on ice during 
treatment (Figure 32A). To confirm these results, I cross-verified the increased 
fluorescence signal using fluorescent microscopy to visualise the same cells used for 
the FACS analysis. The intensity of the fluorescence was consistent with the data from 
the FACS analysis, confirming the results obtained (data not shown). 
 
 A 
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Figure	  32:	   	  Effect	  of	  ASAP1	  knock	  down	  on	  the	  internalization	  of	  
fluorescent	  EGF	  measured	  via	  FACS.	  A.	  The	  graph	  shows	  the	  result	  of	   a	   representative	   experiment.	   The	   silencing	   of	   ASAP1	   clearly	  increases	   the	   fluorescence	   intensity	   compared	   to	   the	   control.	  B.	   The	  efficiency	  of	  the	  knock	  down	  was	  assessed	  by	  means	  of	  Western	  Blot.	  	  
 
4.1.3 Nm23-H1 knockdown rescues the effect of ASAP1 silencing on EGF 
internalization 
 
To determine whether Nm23-H1 expression influences ASAP1-mediated internalization 
of fluorescein-labelled EGF, I silenced Nm23-H1 expression alone or in combination 
with the knock down of ASAP1. The cells that had a reduced amount of ASAP1 showed 
an increase in the fluorescence intensity as in previous experiments (Figure 33A). 
However, this effect was reverted back to the basal level when the silencing of Nm23-
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H1 and ASAP1 were combined. Importantly, the knock down of Nm23-H1 alone did not 
show any effect on the internalization of the receptor. Thus knockdown of Nm23-H1 
may compensate for the silencing of ASAP1. 
 
 	  
	  
Figure	   33:	   Effect	   of	   the	   knock	   down	   of	   ASAP1	   and/or	   Nm23-­‐H1	   on	   the	   internalization	   of	  
fluorescent	  EGF	  measured	  via	  FACS.	  A.	  The	  graph	  shows	  the	  result	  of	  a	  representative	  experiment.	  The	   fluorescence	   intensity	   of	   the	   cells	   treated	   with	   the	   ASAP1	   knock	   down	   is	   clearly	   increased	  compared	   to	   the	   control	   ones	   (white)	   (significance	   indicated	   by	   green	   asterisks).	   No	   effect	   on	   the	  fluorescence	   intensity	   is	   observable	   with	   the	   knock	   down	   of	   Nm23-­‐H1	   (blue	   bars),	   nor	   with	   the	  combination	   of	   Nm23-­‐H1	   and	   ASAP1	   silencing	   (orange	   bars).	   The	   black	   asterisks	   indicate	   the	  significance	  of	  the	  difference	  between	  the	  ASAP1	  knock	  down	  alone	  compared	  to	  the	  double	  silencing.	  
B.	  The	  efficiency	  of	  both	  knockdowns	  was	  assessed	  by	  means	  of	  Western	  Blot.	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4.1.4 Nm23-H1 overexpression shows a similar effect as ASAP1 
knockdown in EGF uptake assays 
 
As knockdown of Nm23-H1 abrogated the increased fluorescence intensity observed 
in the EGF internalization assays after knockdown of ASAP1, I next investigated the 
effect of the overexpression of Nm23-H1 on this process. For this purpose I 
transfected the MDA MB 231 cells with an expression construct for Nm23-H1, with or 
without the silencing for ASAP1. Similar to the previous experiments, the knockdown of 
ASAP1 resulted in an increase of the fluorescence intensity compared to the control 
(Figure 34). The overexpression of Nm23-H1 alone also led to a significant increase in 
the fluorescence intensity relative to the pcDNA-transfected control cells. However, the 
increased fluorescence in these cells was never as pronounced as that obtained with 
the knockdown of ASAP1. Furthermore, concomitant overexpression of Nm23-H1 in 
ASAP1 knockdown cells only increased the fluorescence intensity to the levels 
obtained with overexpression of Nm23-H1 alone, which was significantly lower than 
the increased fluorescence observed after knockdown of ASAP1 alone. These data 
suggest that ASAP1 and Nm23-H1 may act independently to regulate the 
internalization of EFG.  
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Figure	   34:	   Effect	   of	   the	   overexpression	   of	   Nm23-­‐H1	   and/or	   the	   silencing	   of	   ASAP1	   on	   the	  
internalization	   of	   fluorescent	   EGF	   measured	   via	   FACS.	   A.	   The	   graph	   shows	   the	   result	   of	   a	  representative	   experiment.	   The	   asterisks	   in	   the	   bars	   represent	   the	   significance	   versus	   the	   control	  (white).	  The	  fluorescence	  intensity	  of	  the	  cells	  treated	  with	  the	  ASAP1	  knockdown	  is	  clearly	  increased	  compared	   to	   the	   control	   cells	   (significance	   indicated	   by	   green	   asterisks).	   A	   significant	   increase	   in	  fluorescence	  is	  observable	  with	  the	  overexpression	  of	  Nm23-­‐H1	  (blue),	  also	  when	  combined	  with	  the	  silencing	  of	  ASAP1	  (orange).	  The	  black	  asterisks	  indicate	  the	  significance	  of	  the	  difference	  between	  the	  ASAP1	  knock	  down	  alone	  compared	  to	  the	  silencing	  combined	  with	  the	  overexpression	  of	  Nm23-­‐H1.	  B.	  The	  efficiency	  of	  knock	  down	  and	  overexpression	  was	  assessed	  by	  means	  of	  Western	  Blot 
 
4.1.5 Overexpression of h-prune does not influence ASAP1-mediated 
uptake of EGF 
 
Next I investigated whether h-prune modulates the uptake of EGF mediated by ASAP1, 
similar to that observed with Nm23-H1. ASAP1-silenced MDA MB 231 cells were 
transiently transfected with an expression plasmid for h-prune, or with the empty 
vector as a control. All samples were analysed for the uptake of fluorescent EGF as 
before. The results clearly indicate that the overexpression of h-prune does not affect 
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the ability of ASAP1 knockdown to promote the internalization of the EGF-receptor 
complex (Figure 35).  
Therefore, although h-prune is able to bind to ASAP1, it does not appear to affect the 
role of ASAP1 in EGF internalization.  
 
 
Figure	   35:	   Effect	   of	   the	   overexpression	   of	   h-­‐prune	   and/or	   the	   silencing	   of	   ASAP1	   on	   the	  
internalization	   of	   fluorescent	   EGF	   measured	   via	   FACS.	   A.	   The	   graph	   shows	   the	   result	   of	   a	  representative	  experiment.	  The	  asterisks	  within	  the	  bars	  represent	  the	  significance	  versus	  the	  control	  cells.	   The	   fluorescence	   intensity	   of	   the	   cells	   treated	   with	   the	   ASAP1	   knock	   down	   is	   significantly	  increased	  compared	   to	   the	  control	  ones	  (indicated	  by	  green	  asterisks).	  This	   increase	   in	   fluorescence	  intensity	   is	   not	   impaired	   when	   combined	   with	   the	   overexpression	   of	   h-­‐prune	   (orange).	   The	   black	  asterisks	   indicate	   the	   significant	   difference	   between	   the	   ASAP1	   knock	   down	   alone	   compared	   to	   the	  silencing	  combined	  with	  the	  overexpression	  of	  h-­‐prune.	  
B.	  The	  efficiency	  of	  knock	  down	  and	  overexpression	  was	  assessed	  by	  means	  of	  Western	  Blot 
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4.2 Influence of Nm23-H1 and h-prune on ASAP1-mediated 
motility 
 
4.2.1 Effect of ectopic expression of Nm23-H1 and h-prune on ASAP1-
dependent motility 
 
ASAP1 is able to promote motility, most probably via the interaction with other proteins 
through its proline-rich SH3 binding domain (Müller et al., 2010). Both h-prune and 
Nm23-H1 are themselves known to regulate the motility of tumor cells. As h-prune and 
Nm23-H1 are binding partners of ASAP1, I set out to investigate whether these 
proteins interact to influence the ability of ASAP1 to promote invasiveness. 
 
To evaluate whether Nm23-H1 or h-prune influence ASAP1-mediated motility, I 
performed monolayer wound healing assays using MDA MB 231 cells, which have a 
high endogenous expression of ASAP1. The cells were transfected with a siRNA 
specific for ASAP1 alone or together with either Nm23-H1 or h-prune expression 
plasmids. As controls, the cells were transfected with scrambled siRNA and the empty 
vector.  
The analysis of the assays confirmed the role of ASAP1 in promoting cell motility. Cells 
transfected with the siRNA for ASAP1 had a reduced ability to close the wound in the 
monolayer, whereas the control cells moved more rapidly  
Nm23-H1 overexpression had no influence on monolayer wound closure relative to the 
control cells, and furthermore had no effect on the reduced wound closure observed in 
ASAP1 knockdown cells (Figure 36). 
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Figure	  36:	  Effect	  of	   the	  overexpression	  of	  Nm23-­‐H1	  on	  ASAP1-­‐mediated	  motility.	  MDA	  MB	  231	  cells	  were	  transfected	  with	  an	  expression	  plasmid	  for	  Nm23-­‐H1	  alone,	  or	  in	  combination	  with	  a	  siRNA	  against	  ASAP1.	  Controls	  included	  scrambled	  siRNA	  and	  empty	  vector-­‐transfected	  cells,	  as	  well	  as	  cells	  with	   the	   ASAP1	   knockdown	   alone.	  A.	   Representative	   pictures	   of	   the	  monolayer	  wounds	   are	   shown	  from	  the	  beginning	  (t=0)	  and	  the	  end	  (t=48	  hours)	  of	  the	  assay.	  B.	  The	  graph	  shows	  the	  analysis	  of	  a	  representative	  motility	  experiment,	  indicating	  the	  percentage	  of	  wound	  closure	  at	  24,	  32	  and	  48	  hours	  after	   insert	  removal.	  The	  asterisks	   in	   the	  bars	  represent	   the	  significance	  versus	   the	  control	  cells,	   the	  ones	   above	   them	   the	   significance	   between	   the	   indicated	   samples.	   The	   overexpression	   of	   Nm23-­‐H1	  (blue	   bars)	   did	   not	   influence	   the	   motility	   of	   the	   cells.	   The	   knock	   down	   of	   ASAP1	   (green	   bars)	  significantly	   reduced	   the	  motility	  of	   the	   cells	   already	  at	  24	  hours,	   even	   in	   the	  presence	  of	  Nm23-­‐H1	  overexpression	  (orange	  bars).	  Error	  bars	  are	  standard	  error	  (n=60).	  	  
 
On the other hand, h-prune overexpression by itself slightly but significantly reduced 
monolayer wound closure, but again had no observable effect on the enhanced 
reduction in wound closure observed in ASAP1 knockdown cells (Figure 37).  
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Figure	  37:	  Effect	  of	  the	  over	  expression	  and	  h-­‐prune	  on	  ASAP1-­‐mediated	  motility.	  MDA	  MB	  231	  cells	  were	  transfected	  with	  an	  expression	  plasmid	  for	  h-­‐prune	  alone,	  or	  in	  combination	  with	  a	  siRNA	  against	  ASAP1.	  Controls	  included	  scrambled	  siRNA	  and	  empty	  vector-­‐transfected	  cells,	  as	  well	  as	  cells	  with	   the	   ASAP1	   knockdown	   alone.	  A.	  Representative	   pictures	   of	   the	  monolayer	  wounds	   are	   shown	  from	  the	  beginning	  (t=0)	  and	  the	  end	  (t=48	  hours)	  of	  the	  assay.	  B.	  The	  graph	  shows	  the	  analysis	  of	  a	  representative	  motility	  experiment,	  indicating	  the	  percentage	  of	  wound	  closure	  at	  24,	  32	  and	  48	  hours	  after	   insert	  removal.	  The	  asterisks	   in	   the	  bars	  represent	   the	  significance	  versus	  the	  control	  cells,	   the	  ones	   above	   them	   the	   significance	   between	   the	   indicated	   samples.	   The	   overexpression	   of	   h-­‐prune	  slightly	   but	   significantly	   reduced	   the	   motility	   of	   the	   cells.	   The	   knock	   down	   of	   ASAP1	   (green)	  significantly	   reduced	   the	  motility	   of	   the	   cells	   already	   at	   24	   hours,	   even	   in	   the	   presence	   of	   h-­‐prune	  overexpression	  (orange).	  Error	  bars	  are	  standard	  error	  (n=60).	  	  
 
Both the knock down of ASAP1 and the over expression of Nm23-H1 and h-prune were 
efficient throughout the duration of the assay, as shown in the Western Blot (Figure 
38), confirming the reliability of the experiment.  
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Figure	   38:	   Western	   blots	   showing	   the	  
efficiency	   of	   the	   transfections.	   Lysates	   were	  prepared	   at	   the	   beginning	   of	   the	   assay	   (t=0)	  and	  at	  the	  end	  (t=48),	   to	  verify	  the	  persistence	  of	   both	   the	   knock	   down	   of	   ASAP1	   and	   the	  overexpression	  of	  Nm23-­‐H1	  (upper	  figure)	  and	  of	  h-­‐prune	  (lower	  figure).	  
 
 
 
4.2.2 Nm23-H1 and ASAP1 silencing both reduce the motility of MDA-MB-
231 cells 
 
To further explore the possibility that the interaction of Nm23-H1 with ASAP1 might be 
necessary for ASAP1 to exert its motility promoting activity, I silenced both proteins 
either together or individually. As before, the silencing of ASAP1 decreased the motility 
of the cells. Silencing of Nm23-H1 also significantly reduced cell motility in these 
assays to the same extent as ASAP1 silencing. However, the decreased cell motility 
observed after the silencing of ASAP1 was not influenced by the additional silencing of 
Nm23-H1 (Figure 39). Western blot analysis confirmed that knockdown of the proteins 
was efficient (Figure 40). 
Due to the lack of a suitable antibody against human h-prune, it was not possible to 
establish silencing of this protein. 
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Figure	   39:	   Effect	   of	   Nm23-­‐H1	   siRNA	   on	   ASAP1	   mediated	   motility.	   MDA	   MB	   231	   cells	   were	  transfected	   with	   siRNA	   against	   either	   ASAP1	   or	   Nm23-­‐H1,	   or	   a	   combination	   of	   the	   two.	   Controls	  comprised	  scrambled	  siRNA-­‐transfected	  cells.	  A.	  Representative	  pictures	  of	  monolayer	  wounds	  taken	  at	   the	  beginning	  of	   the	   assay	   (t=0)	   and	   at	   the	   end	   (t=48	  hours).	  B.	   Graph	   showing	   the	   analysis	   of	   a	  representative	  motility	  experiment.	  The	  asterisks	  within	  the	  bars	  represent	  the	  significance	  versus	  the	  control	   cells,	   the	   ones	   above	   them	   the	   significance	   between	   the	   indicated	   samples.	   Error	   bars	   are	  standard	  error	  (n=60).	  The	  silencing	  of	  ASAP1	  (green	  bars)	  and	  Nm23-­‐H1	  (blue	  bars)	  both	  reduce	  the	  motility	  of	  the	  cells,	  however	  the	  combination	  of	  the	  two	  does	  not	  result	  in	  a	  synergistic	  effect	  (orange	  bars).  
Figure	  40:	  Western	  blot	  showing	  the	  efficiency	  of	   the	   transfections.	   Lysates	   were	   prepared	   at	  the	  beginning	  of	  the	  assay	  (t=0)	  and	  at	  the	  end	  (t=48),	   to	   verify	   the	   persistence	   of	   both	   the	  knock	  down	  of	  ASAP1	  and	  Nm23-­‐H1	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4.3 The SH3 binding domain of ASAP1 
 
4.3.1 Screening of SH3 domain arrays and identification of ASAP1 SH3 
domain partners 
 
ASAP1 is able to bind to several proteins, such as c-Src and Crk, via its proline-rich 
SH3 binding domain that interacts with the SH3 domain in these proteins. A point 
mutation in the proline-rich domain (R811A) is sufficient to impair the binding of 
ASAP1 to these proteins (Brown et al., 1998). In previous work, we have shown that 
ASAP1-mediated cell motility is required for its SH3-binding domain, because the 
R811A mutation led to a significant reduction in the ability of ASAP1 to promote cell 
motility and adhesiveness in vitro, and attenuated its metastasis-promoting activity in 
vivo, compared to the wild type protein (Müller et al. 2010). This strongly suggests that 
the SH3 binding domain is critical for the metastasis promoting function of ASAP1.  
 
To gain further insight into how ASAP1 regulates cell motility and metastasis, I set out 
to identify additional potential binding partners of ASAP1 that interact with its proline 
rich region, and then to determine if these partners are able to influence the motility-
promoting activity of ASAP1. I also wanted to determine whether h-prune and Nm23-
H1 affect the ability of ASAP1 to bind to these SH3 domain proteins. For this purpose, I 
used a commercially available SH3 domain array containing 38 recombinant proteins, 
all of which bear an SH3 domain (see “Materials and Methods” for protocol details).  
 
The array was incubated with lysates of 293T cells transiently transfected with Flag-
tagged ASAP1, and probed with the specific anti-tag antibody. Signals were obtained 
for already-known interaction partners of ASAP1, such as cortactin and c-Src, which 
acted as positive controls and confirmed the reliability of the assay (Figure 41). In 
addition, the presence of several other positive signals identified new potential 
candidates that may bind ASAP1 via the SH3 binding domain and possibly affect the 
activity of ASAP1.  
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Figure	  41:	  The	  SH3	  domain	  array.	  The	  spots	  correspond	  to	  the	  interaction	  of	  ASAP1	  with	  the	  indicated	  proteins,	   confirming	   already	   known	   interaction	   partners	   of	   ASAP1,	   highlighted	   by	   a	   circle.	   New	  putative	  binding	  partners	  emerged	  from	  this	  assay. 
 
4.3.2 Nm23-H1 and h-prune do not interfere with the binding of ASAP1 to 
SH3 domain-bearing proteins 
 
I next investigated whether h-prune and Nm23-H1 influence the interaction of ASAP1 
with SH3 domain-containing partners. For this purpose, I repeated the SH3 domain 
array experiment using lysates of cells that had been co-transfected with ASAP1 and 
either an empty vector, or expression constructs for h-prune or Nm23-H1. After having 
assessed the efficiency of transfection via Western Blot, I incubated the lysates with 
the SH3 domain array and performed the assay. The only difference in signal intensity 
between the ASAP1-transfected cells, and the ASAP1-transfected cells that were co-
transfected with Nm23-H1 or h-prune was a reduction in the signal intensity for 
cortactin with the h-prune transfected sample, possibly suggesting a reduced 
interaction of ASAP1 with cortactin under these conditions (Figure 42A). To verify this 
observation, I created a custom dot blot array using the same recombinant cortactin 
protein used in the SH3 domain assay (Figure 42B). This second experiment revealed 
that neither the overexpression of h-prune, nor of Nm23-H1 were able to affect the 
strong binding of ASAP1 to cortactin. This suggests that Nm23-H1 and h-prune do not 
affect the ability of ASAP1 to interact with protein partners via its SH3 binding domain. 
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Figure	   42:	  A.	   SH3	   domain	   arrays	   incubated	   with	  lysates	  of	  293T	  cells	  co-­‐transfected	  with	  Flag-­‐tagged	  ASAP1	  and	  1.	   pcDNA;	  2.	  Nm23-­‐H1;	  3.	   h-­‐prune.	  The	  arrays	   were	   then	   incubated	   with	   an	   anti-­‐Flag	  antibody,	   to	   visualize	   the	   binding	   of	   ASAP1	   to	   the	  SH3	   proteins.	   The	   pattern	   of	   interaction	   is	  comparable	   to	   the	   one	   obtained	   previously	   (Figure	  41).	   The	   box	   indicates	   the	   cortactin	   spots	   on	   the	  arrays	  No	  difference	  can	  be	  observed	  between	  array	  1	  and	  2,	  whereas	  there	  seem	  to	  be	  a	  signal	  reduction	  in	   blot	   3,	   suggesting	   an	   effect	   of	   h-­‐prune	   on	   the	  binding	   of	   ASAP1	   to	   SH3	   proteins.	   B:	   Dot	   plot.	   A	  PVDF	   membrane	   spotted	   with	   the	   same	  recombinant	   GST-­‐fused	   cortactin	   used	   in	   the	   SH3	  domain	   array	  was	   incubated	  with	   the	   same	   lysates	  and	   antibodies	   as	   in	   Figure	   42A.	   Membrane	   4	   was	   incubated	   with	   the	   secondary	   antibody	   only	  (negative	  control)	  and	  membrane	  5	  with	  an	  anti-­‐GST	  antibody,	  to	  confirm	  the	  presence	  of	  the	  spotted	  cortactin	  (positive	  control).	  The	  spots	  are	  identical,	  confirming	  that	  neither	  the	  presence	  of	  Nm23-­‐H1	  nor	  of	  h-­‐prune	  can	  affect	  the	  binding	  of	  ASAP1	  to	  the	  SH3	  protein	  cortactin.	  	  
 
4.3.3 SLK is a novel binding partner of ASAP1 
 
Among the putative novel binding partners that emerged from the screening of the 
SH3 domain array, one was of particular interest for us, namely the Ste20-like kinase 
(SLK). This protein has been shown to play a role in motility (Wagner et al., 2008), and 
like ASAP1 localizes to membrane ruffles in migrating fibroblasts (Wagner et al., 
2002). Interestingly, SLK has also been shown to play a role in ErbB2-driven breast 
cancer motility (Roovers et al., 2009). I therefore set out to try and confirm the 
interaction between these to proteins by means of co-immunoprecipitation, as a first 
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step towards investigating whether SLK might contribute to ASAP1-mediated cell 
motility. 
To this end I transfected a Flag-tagged form of ASAP1 into 293T cells that have a low 
expression of endogenous ASAP1. An anti-flag tag antibody was then used to 
immunoprecipitate the ASAP1 from lysates of the cells. The precipitates were resolved 
by SDS-PAGE, then probed with anti-SLK antibodies to determine whether ASAP1 and 
SLK interact. The immunoprecipitation confirmed the interaction of ASAP1 with the 
endogenous SLK protein, suggesting that SLK is a new interaction partner of ASAP1 
that might cooperate with ASAP1 to regulate motility and invasion (Figure 43). 
 
Figure	  43:	  SLK	  co-­‐immunoprecipitation.	   	  293T	  cells	  were	  transfected	  with	  Flag-­‐tagged	  ASAP1	  and	  the	  tag	  was	  used	  to	  precipitate	  this	  protein	  with	  a	  G	  protein-­‐coupled	  resin.	  The	  SLK	  antibody	  was	  then	  used	  to	  verify	  the	  presence	  of	  this	  protein	  in	  the	  immunocomplex	  (upper	  blot).	  The	  first	  lane	  on	  the	  left	  corresponds	  to	  the	  whole	  lysate	  and	  serves	  as	  a	  control	  for	  the	  presence	  of	  both	  proteins.	  As	  controls	  (lanes	   3-­‐6),	   following	   conditions	  were	   applied:	   isotype	   control	   with	   resin,	   no	   resin,	   isotype	   control	  without	  resin,	  no	  antibody.	  The	  blot	  was	  then	  stripped	  and	  incubated	  with	  an	  anti	  ASAP1	  antibody,	  to	  verify	  the	  efficiency	  of	  the	  immunoprecipitation.	  The	  presence	  of	  the	  band	  in	  the	  second	  lane	  confirms	  the	  interaction	  between	  ASAP1	  and	  SLK.	  
 
4.3.4 Overexpression of h-prune and Nm23-H1 does not affect the binding 
of ASAP1 to SLK 
 
The results obtained with the SH3 domain arrays already suggested that neither h-
prune nor Nm23-H1 affect the binding of ASAP1 to SH3 domain-bearing interaction 
partners. To confirm this finding, I repeated the co-immunoprecipitation of SLK in 
293T cells co-transfected with Flag-tagged ASAP1 and either Nm23-H1 or h-prune 
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expression constructs, or with empty vector as a control. The blot shows that neither h-
prune nor Nm23-H1 were able to affect the binding of ASAP1 to SLK (Figure 44A), 
again suggesting that h-prune and Nm23-H1 interact with domains on ASAP1 other 
than the proline-rich SH3 binding domain, and also do not interfere with the ability of 
ASAP1 to bind to SH3 domain-bearing proteins via its SH3 binding domain. 
 
A        B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure	  44:	  Co-­‐immunoprecipitation	  of	  SLK	  in	  cells	  transfected	  either	  with	  Nm23-­‐H1,	  h-­‐prune	  or	  the	  appropriate	   control.	   A.	   The	   left	   lane	   shows	   the	   two	   proteins	   in	   the	   normal	   lysate.	   This	   blot	   was	  incubated	   first	  with	   the	   SLK	   antibody,	   to	   show	   the	   presence	   of	   this	   protein	   in	   the	   immunocomplex	  (upper	  blot),	  and	  then	  stripped	  and	  re-­‐incubated	  with	  an	  anti	  ASAP1	  antibody,	  to	  verify	  the	  efficiency	  of	   the	   immunoprecipitation.	   (lower	   blot).	   Neither	   the	   overexpression	   of	   h-­‐prune	   nor	   of	   Nm23-­‐H1	  affects	  the	  ability	  of	  ASAP1	  to	  bind	  to	  SLK.	  B.	  The	  transfection	  of	  the	  plasmids	  was	  checked	  via	  Western	  blot	  
 
4.3.5 Cloning of human Ste20 Like Kinase 
 
Due to the known role of SLK in promoting motility, and having shown its interaction 
with ASAP1, I wanted to verify whether these two proteins act synergistically to 
promote the motility in MDA MB 231 cells. First I needed to clone the human SLK gene 
into an appropriate expression vector. For this purpose I used the pcDNA™3.1 ⁄ V5-His 
TOPO® TA kit (Life Science, Darmstadt) and proceeded as described in “Materials and 
Methods”. After having successfully cloned the gene, I verified the correctness of the 
plasmid by control digestion and sequencing of the plasmid. I also checked the ability 
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of the expression plasmid to drive the expression of SLK in 293T cells using Western 
blot analysis (Figure 45).  
 
Figure	  45:	  Blot	  showing	  the	  expression	  of	  the	  His-­‐tagged	  SLK	  in	  the	  transfected	  231T	  cells	  (right	  lane)	  compared	  to	  control	  cells.	   The	   upper	   part	   of	   the	   blot	   was	   incubated	   with	   the	  specific	  anti	  His	  antibody,	  while	  the	  lower	  part	  was	  incubated	  with	   an	   anti	   actin	   antibody	   as	   a	   loading	   control.	   This	   result	  confirmed	  the	  correctness	  of	  the	  expression	  plasmid.	  
  
4.3.6 SLK regulates cell motility independently of ASAP1 in MDA MB 231 
cells 
 
As ASAP1 and SLK interact and both proteins are involved in motility regulation, I 
wanted to investigate whether SLK cooperates with ASAP1 to promote motility, or 
whether these two proteins act independently. For this purpose I performed monolayer 
wound healing assays using MDA MB 231 cells transfected with ASAP1 siRNA alone, 
or in combination with either SLK siRNA or the expression plasmid for SLK. 
As expected, knock down of either protein was able to significantly reduce the motility 
of the cells, although not to the same extent: ASAP1 silencing was more efficient. The 
combination of the two knockdowns did not show any additional effect on monolayer 
wound closure over and above that exerted by ASAP1 silencing (Figure 46). 
Overexpression of SLK increased the closure rate of the monolayer wound as 
expected. Importantly, reduced wound closure upon the knockdown of ASAP1 was 
partially rescued by ectopic expression of SLK (Figure 47), suggesting that SLK 
regulates cell motility independently of its interaction with ASAP1.  
         
 
 
 
 
 
 93 
 
	  
Figure	   46:	   Effect	   of	   the	   knock	   down	  
of	   SLK	   combined	  with	  ASAP1	  knock	  
down	   on	   cell	   motility.	   A.	  Representative	   pictures	   of	   monolayer	  wounds	   taken	   at	   the	   beginning	   of	   the	  assay	   (t=0)	   and	   at	   the	   end	   (t=48).	   B.	  Graph	   showing	   the	   analysis	   of	   a	  representative	   motility	   experiment.	  The	   gap	   closure	   was	   measured	   at	   24,	  32	  and	  48	  hours	  after	  insert	  removal.	  The	  width	  of	  the	  two	  cell	  fronts	  at	  the	  beginning	  of	  the	  assay	  was	  considered	  as	  100%.	  The	  asterisks	  within	  the	  bars	  represent	  the	  significance	  versus	  the	  control.	  The	  other	  asterisks	  represent	  the	  significance	  of	  the	  difference	  between	  SLK	  knock	  down	  cells	  (blue	  bars)	  compared	   to	   the	   double-­‐knock	   out	   cells	   (orange	   bars),	   and	   of	   the	   double	   knock	   out	   cells	   to	   cells	  transfected	   with	   the	   ASAP1	   siRNA	   alone	   (green	   bars).	   Error	   bars	   are	   standard	   error	   (n=60).	   Both	  ASAP1	  and	  SLK	  knock	  down	  were	  able	  to	  reduce	  the	  motility,	  although	  to	  a	  different	  extent.	  
C.	  Western	  blot	  showing	  the	  efficiency	  of	  the	  knock	  down	  at	  the	  beginning	  of	  the	  assay	  (t=0)	  and	  at	  the	  end	  (t=48). 
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Figure	   47:	   Effect	   of	   the	  
overexpression	  of	  SLK	  combined	  with	  
ASAP1	  knock	  down	  on	  cell	  motility.	  A.	  Example	  pictures	  of	  the	  wound	  taken	  at	  the	   beginning	   of	   the	   assay	   (t=0)	   and	   at	  the	   end	   (t=48).	   B.	   Graph	   showing	   the	  analysis	   of	   a	   representative	   motility	  experiment.	   The	   asterisks	   within	   the	  bars	   represent	   the	   significance	   versus	  the	  control	  cells.	  The	  other	  asterisks	  represent	  the	  significance	  of	  the	  difference	  between	  ASAP1	  knock	  down	  cells	  overexpressing	  SLK	  (orange	  bars)	  compared	  to	  ASAP1	  knock	  down	  cells	  only	  (green	  bars).	  Error	  bars	  are	  standard	  error	  (n=60).	  The	  knock	  down	  of	  ASAP1	  significantly	  reduced	  the	  motility	  of	  the	   cells,	  whereas	   the	  overexpression	  of	   SLK	   results	   in	   an	   increase	  of	   the	   cell	  motility.	  This	   effect	   is	  almost	  unchanged	  by	  the	  simultaneous	  knock	  down	  of	  ASAP1.	   
C.	  Western	  blot	  showing	  the	  efficiency	  of	  the	  transfections	  at	  the	  beginning	  of	  the	  assay	  (t=0)	  and	  at	  the	  end	  (t=48). 	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Taken together, these results indicate that although ASAP1 and SLK interact with each 
other, and are both able to affect the motility of the cells, they are likely to do so via 
independent mechanisms. 
 
4.3.7 ASAP1 knock out mouse embryonic fibroblasts have impaired 
motility 
 
The effects of ASAP1 binding partners on ASAP1-dependent motility have been all 
analyzed in the context of “loss of function” experiments using the silencing of the 
ASAP1 gene in the MDA MB 231. These cells have already a very high level of 
expression of ASAP1, making them unsuitable for performing “gain of function” 
analysis. For this purpose I took advantage of the ASAP1 knockout mice available in 
the laboratory, and prepared primary cultures of MEFs from wild type and knock out 
embryos. I reasoned that the knock out cells would enable me to analyze the effects of 
a “gain of function”, namely what happens when ASAP1 is ectopically expressed on a 
knockout background.  
I first analyzed the basal motility activity of the MEFs in the presence or absence of 
ASAP1. I performed the wound healing assays with three lines each per genotype. The 
assays clearly showed that the fibroblasts derived from the ASAP1 knockout mice had 
a statistically significant reduced motility compared to the wild type MEFs (Figure 48 
and Figure 49). This was not line dependent, and was reproducible over three 
experiments.	  
	  
	  
	  
Figure	   48:	   Representative	   experiment	  showing	   the	  difference	   in	  motility	   in	  wild	  type	   versus	   ASAP1	   knock	   outs	   MEFs.	  Error	   bar	   is	   standard	   error	   (n=24	   in	   A,	  n=72	  in	  B).	  A.	  Mean	  of	  three	  different	  cell	  lines	   B.	   Results	   of	   the	   pooled	   individual	  cell	  lines.	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Figure	   49:	   A.	   MEFs	   from	   ASAP1	   knockout	   mice	  have	   impaired	   motility.	   Representative	   pictures	  showing	   the	   difference	   between	   the	   ability	   to	  close	   the	   gap	   of	   the	  wild	   type	  MEFs	   (left)	   versus	  the	  knockout	  cells	  (right)	  24	  hours	  after	  removing	  the	   insert.	   B.	   Western	   blot	   showing	   the	   missing	  expression	   of	   the	   ASAP1	   gene	   in	   the	   knockout	  MEFs  
 
4.3.8 SLK overexpression does not influence ASAP1-mediated motility in 
MEFs 
 
MEFs lacking the ASAP1 gene have a reduced ability to close monolayer wounds. In 
MDA MB 231 breast tumor cells, overexpression of SLK partially rescues the reduction 
in motility caused by knockdown of ASAP1 (Figures 46 and 47), suggesting that the 
two proteins regulate cellular motility independently. To verify this notion I transfected 
the ASAP1 knock out and wild type MEFs with the expression plasmid for SLK. 
 97 
Additionally, I performed motility experiments with the ASAP1 knockout cells 
transfected with the ASAP1 expression plasmid and the mutant R14, which lacks one 
proline in the SH3 binding domain that is critical for ASAP1-mediated motility.  
Due to the low transfection efficiency of the primary MEFs, in order to perform the 
assay I first had to FACS sort MEFs that were co-transfected with the plasmid of 
interest and a GFP-expression plasmid (Figure 50).  
  
Figure	   50:	   	   FACS	   sort	   of	   co-­‐transfected	   MEFs.	   Wild-­‐type	   and	   ASAP1	   knock	   out	   MEFs	   were	   co-­‐transfected	   with	   a	   GFP-­‐expressing	   plasmid	   and	   either	   an	   empty	   vector	   as	   a	   control	   (pcDNA),	   or	  plasmids	  expressing	  the	  protein	  of	  interest	  (SLK,	  ASAP1	  or	  R14).	  The	  control	  plot	  shows	  the	  absence	  of	  fluorescence	  in	  cells	  not	  transfected	  with	  the	  GFP-­‐expressing	  plasmid.	  The	  population	  in	  green	  in	  the	  other	  plots	   represents	   the	   cells	   that	  have	  been	   successfully	   co-­‐transfected	   (efficiency	   shown	  bottom	  right	  of	  the	  plot).	  	  
 
In both the wild type and knockout MEFs, the overexpression of SLK induced an 
increase in motility to a similar extent (Figure 51). This indicates that the motility 
promoting ability of SLK is independent of the presence of ASAP1. Furthermore, 
transfection of ASAP1 into the knockout MEFs caused a complete recovery in motility 
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back to the wild type levels. As expected, this did not happen when the cells were 
transfected with the R14 mutant (Figure 51).  
 
A 
 
 
 
 
 
 
 
 
 
 
 
B  
 
 
 
 
	  
	  
Figure	  51:	  A.	  Representative	  pictures	  showing	  the	  effect	  on	  the	  motility	  of	  wild	  type	  and	  ASAP1	  knock	  out	  MEFs	  of	  the	  transfection	  of	  various	  plasmids.	  B.	  Graph	  showing	  the	  analysis	  of	  one	  representative	  motility	   assay.	   Both	   wild	   type	   and	   ASAP1-­‐knock	   out	   MEFs	   were	   transfected	   with	   SLK	   or	   with	   the	  appropriate	  control,	  and	  their	  wound	  closure	  measured.	  The	  ASAP1-­‐knock	  out	  MEFs	  were	  additionally	  transfected	   with	   ASAP1	   and	   R14	   expression	   plasmids.	   Error	   bars	   are	   standard	   error	   (n=3).	   Blue	  asterisks	  represent	  the	  significance	  versus	  the	  knockout	  control	  cells.	  	  
 
 99 
Again, these experiments underscore the importance of the SH3 binding domain of 
ASAP1 in promoting the motility of the cells, but rule out the possibility that SLK is 
involved in this mechanism, confirming the results obtained with the MDA MB 231 
cells. 
 
4.4 ASAP1 as a multidomain protein  
 
4.4.1 Establishment of a Fast Protein Liquid Chromatography System for 
analysis of ASAP1-containing protein complexes 
 
ASAP1 is a multi domain adaptor protein that binds to a wide variety of other proteins 
through its different domains. Both Nm23-H1 and h-prune, which in tumor cells form a 
complex, have been shown via co-immunoprecipitation to interact with ASAP1. 
However, my results indicate that these two proteins do not influence the activities of 
ASAP1 that I analyzed, namely the regulation of receptor internalization and the 
promotion of motility. This raised the question of whether the binding of these two 
proteins to ASAP1 is relevant in vivo. Therefore I set out to investigate the presence of 
Nm23-H1 and h-prune in ASAP1-containing protein complexes extracted from cells. To 
this end I used a Fast Protein Liquid Chromatography (FPLC) system to perform size 
exclusion chromatography using a gel filtration column.  
I first established a calibration curve of the column with specific molecular weight 
markers. Blue dextran (molecular weight approx. 2,000,000Da) was used to 
determine the void volume (Vo) of the column. This is column-specific, and is the 
volume of effluent required for the elution of a large completely excluded molecule. 
Then six proteins with known molecular weights were run through the column, and 
their elution volume (Ve) assessed (Table 3). The Ve corresponds to the peak of elution 
of the given protein. Plotting the logarithms of the known molecular weights of protein 
standards versus their respective Ve/Vo values produced a linear calibration curve 
(Figure 52). With the help of the calibration curve, I was able to calculate the 
corresponding approximate molecular weight for each fraction, and therefore to 
determine the size of the ASAP1-containing complexes.  
 
 100 
carbonic 
anhydrase
albumin
alcohol
dehydrogenase
ß-amylase
thyroglobulin
apoferritin
10
100
1000
1.40 1.60 1.80 2.00 2.20
Ve/Vo
M
W
, k
D
a
  MW, kDa Ve Ve/Vo Fraction no. 
carbonic anhydrase 29 20.5 2.12 42 
albumin 66 19.1 1.97 36 
alcohol dehydrogenase 150 18.2 1.88 33 
ß-amylase 200 17.7 1.83 31 
apoferritin 443 16.5 1.71 26 
thyroglobulin 669 15.2 1.57 21 
blue dextran 2000 9.7   
 
Table	   3:	   	   Molecular	   weights	   and	   elution	   volumes	   of	   the	   protein	   standards	   used	   for	   the	  
calibration	  curve.	  Ve	  is	  the	  volume	  of	  elution	  that	  corresponds	  to	  the	  peak	  of	  the	  given	  protein.	  Vo	  is	  the	  void	  volume	  of	  the	  column.	  The	  ratio	  between	  these	  two	  values	  is	  used	  to	  create	  a	  calibration	  curve	  
(Figure	  52).	  
 
Figure	  52:	  The	  calibration	  curve	  for	  the	  column.	  The	  Ve/Vo	  values	  for	  each	  protein	  standard,	  which	  depend	   on	   their	   elution	   volume	   Ve,	   were	   plotted	   against	   their	   known	   molecular	   weights	   in	   a	  logarithmic	   graph.	   The	   resulting	   curve	   was	   used	   to	   determine	   the	   unknown	  molecular	   weight	   of	   a	  protein	  or	  of	  a	  protein	  complexes	  eluting	  from	  the	  column	  by	  interpolation	  of	  their	  Ve. 
 
The efficiency of the separation depends on the fraction size and number. To be sure 
that these two parameters were optimized in my system, I loaded a cell lysate onto the 
column, performed a separation, and loaded the collected fractions onto SDS-PAGE 
gels, which I stained to visualize the proteins. The gels obtained showed a good 
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separation pattern with clearly visible, discrete bands, indicating that the parameters 
used for the separation were suitable (Figure 53). 
	  
	  
Figure	  53:	  Separation	  of	  cell	  lysate	  proteins.	  Fractions	  collected	  after	  separation	  of	  the	  MDA	  MB	  231	  lysate	  were	  loaded	  onto	  SDS-­‐PAGE	  gels	  and	  stained	  with	  Coomassie.	  The	  discrete	  bands	  visible	  and	  the	  absence	   of	   a	   “smear”	   show	   how	   the	   separation	   strategy	   chosen	   allows	   to	   elute	   distinct	   fractions	  corresponding	  to	  molecular	  weights	  from	  250	  kDa	  (upper	  band	  of	  the	  molecular	  weight	  marker)	  to	  28	  kDa	  (lower,	  red	  band	  of	  the	  molecular	  weight	  marker).	  
 
4.4.2 Endogenous ASAP1 protein complexes do not co-elute with h-prune 
and Nm23-H1 in size exclusion FPLC 
 
To analyse ASAP1-containing protein complexes, I transfected MDA MB 231 cells with 
expression plasmids of tagged Nm23-H1 or h-prune, and prepared cell lysates that 
were applied to the column and separated as described in “Materials and Methods”. 
The fractions were collected, and a set of SDS-PAGE gels for each protein of interest 
(ASAP1, h-prune and Nm23-H1) was run and Western blotted. The incubation of the 
membranes with the specific anti-tag antibodies showed that h-prune and Nm23-H1 
indeed co-elute in similarly sized high molecular weight complexes larger than their 
own individual molecular weight, consistent with their reported interaction (Figure 26). 
Nevertheless, I was unable to detect a signal for these proteins in fractions in which 
endogenous ASAP1 eluted. According to the molecular weight of the mature protein 
(130 kDa), ASAP1 in monomeric form was expected to elute around fraction no. 33 
(see Table 3), but it was already detectable in fraction 13, which corresponds 
approximately to 700 kDa. This indicates that ASAP1 is indeed part of a high molecular 
weight protein complex, and that the gel filtration did not disrupt these interactions. 
However, h-prune and Nm23-H1 did not co-elute with these high molecular weight 
ASAP1-containing complexes, thus suggesting that they may not interact substantially 
with ASAP1 in vivo. Nevertheless, the results clearly demonstrate that ASAP1 
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monomers interact with other proteins as part of a protein complex. The bands 
staining with ASAP1 antibodies found in the elution fractions of Nm23-H1 and h-prune 
visible in blot C are much smaller that the normal size of the ASAP1 protein (Figure 54) 
might correspond for example to unglycosylated precursors of ASAP1, ASAP1 
degradation products, or proteins bound non-specificially by the ASAP1 antibodies.  
 
 
 
Figure	  54:	  Blots	  showing	  the	  separation	  of	   lysates	  of	  MDA	  MD	  231	  cells.	  Blot	  A	  and	  B	  show	  the	  lysate	   eluate	   of	   cells	   transfected	   with	   tagged	   h-­‐prune	   (A)	   and	   Nm23-­‐H1	   (B),	   respectively,	   and	  incubated	  with	   the	   corresponding	   antibody	   (anti-­‐flag	   for	   blot	   A,	   anti-­‐Nm23-­‐H1	   for	   blot	   B).	   The	   red	  boxes	   in	   the	   left	   lane	   indicate	   the	  monomeric	   protein	   bands	   visible	   in	   total	   lysate,	   as	   a	   control.	   	   As	  highlighted	   by	   the	   black	   box,	   the	   bands	   of	   the	   two	   proteins	   appear	   at	   the	   same	   fraction	   number,	  consistent	   with	   their	   interaction.	   Blot	   C	   corresponds	   to	   the	   fractions	   obtained	   from	   the	   non-­‐transfected	  cell	  lysate,	  incubated	  with	  the	  anti-­‐ASAP1	  antibody.	  ASAP1	  protein	  elutes	  mainly	  as	  a	  high	  molecular	  weight	  protein	  complex	  (blue	  box),	  indicative	  of	  its	  interaction	  with	  other	  binding	  partners.	  Note,	  however,	  that	  neither	  Nm23-­‐H1	  nor	  h-­‐prune	  protein	  is	  present	  in	  the	  corresponding	  blots	  at	  this	  molecular	  weight.	   The	   bands	   in	   blot	   C	   that	   are	   visible	   in	   correspondence	   of	   the	   black	   box	  might	   be	  unglycosylated	  precursors	  of	  ASAP1.	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5. DISCUSSION 
 
5.1 Summary of main findings 
 
During my PhD project I analysed the effect of different, newly-discovered ASAP1 
interacting proteins on the ability of ASAP1 to promote EGF receptor internalization 
and cell motility. Nm23-H1 and h-prune, two proteins involved in the control of motility 
and metastasis, have been shown by the laboratory of Prof. Zollo to co-
immunoprecipitate with ASAP1. However, in the highly metastatic breast cell line MDA 
MB 231, no substantial evidence to support a role for Nm23-H1 or h-prune in 
regulating the activity of ASAP1 was obtained. Furthermore, although size exclusion 
chromatography confirmed that most ASAP1 protein in MDA MB 231 cells is part of 
high molecular weight protein complexes, Nm23-H1 and h-Prune are not major 
components of these complexes. 
 
ASAP1 is able to bind to several proteins via its SH3 domain, and previous results 
already suggest that this domain is responsible for the motility-promoting activity of 
ASAP1. Using an array of purified recombinant SH3 domain-containing proteins I was 
able to discover SLK as a new binding partner of ASAP1, and confirmed their 
interaction using co-immunoprecipitation. Nevertheless, other results I obtained 
indicate that SLK and ASAP1 regulate and promote motility independently of each 
other. This was confirmed in MDA MB 231 cancer cells, and in ASAP1-knock out and 
wild type MEFs. The experiments with the MEFs also further substantiate the 
importance of the SH3 binding domain of ASAP1 in its motility-promoting activity. 
Together these data cast further light of the interaction partners of ASAP1 and its role 
in the regulation of EGFR internalization and cell motility.  
 
5.2 ASAP1 regulates EGF internalization.  
 
It is known that EGF, its receptor and downstream signalling pathways are often 
deregulated in tumors. Several studies indicate that regulation of the internalization of 
EGFR also has an impact on cell migration, and thus in the context of a tumor cell 
alterations in the regulation of these process may affect invasion and metastasis 
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(Bremm et al., 2008; Roepstorff et al., 2008; Muller et al., 2009). As ASAP1 regulates 
the internalization of EGF (Nie et al., 2006), I first examined if the metastasis-
promoting activity of ASAP1 could be mediated by its ability to regulate EGFR 
internalization. 
 
To investigate the effects of ASAP1 on receptor uptake and vesicle trafficking, I first 
designed an assay based on the findings of Nie and colleagues who investigated the 
role of the BAR domain of ASAP1 in vesicle trafficking and uptake of EGFR (Nie et al., 
2006). The procedure described in the paper used fluorescence microscopy as 
readout of the internalization rate of fluorescent EGF. This method has some 
weaknesses because the image analysis does not discriminate between unspecifically, 
surface bound EGF and the internalized growth factor-receptor complex. Other 
investigators performed an accurate analysis of the dynamics of EGFR internalization, 
and compared confocal microscopy with FACS analysis (Schmidt-Glenewinkel et al., 
2009). Although confocal microscopy provided useful information about the kinetics of 
internalization, the FACS analysis resulted in a more accurate description of the 
process. This was due mainly to the increased sample size of the method: 10000 cells 
in the FACS analysis compared to 30 cells analysed with the microscope. The overall 
results coincided, but the FACS analysis proved to be a more sensitive tool to detect 
the trafficking of the receptor. Indeed, other authors have used the FACS method with 
analogous protocols to analyse EGFR internalization (Duan et al., 2003; Lidke et al., 
2004; Wang et al., 2005). Given the advantages of the FACS analysis, I opted to use 
this procedure to analyse the effect of ASAP1 on the internalization of fluorescent EGF.  
An important improvement in the protocol that I developed was the use of a stripping 
step, which removes the surface-bound EGF and gives therefore a more specific 
indication about the amount of internalized EGF. 
 
Using the optimized assay, I reproducibly observed that the specific and efficient 
silencing of ASAP1 resulted in an increase in the intracellular fluorescence after 
treatment with fluorescein-coupled EGF. At first sight this result is perhaps 
counterintuitive, because it would appear to suggest that silencing of ASAP1 increases 
uptake of EGF. However, published data indicate that the reverse is in fact true, 
because reduced ASAP1 activity slows vesicle trafficking, resulting in an accumulation 
of the growth factor intracellularly, thereby increasing the fluorescent signal. For 
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example, this has been demonstrated in studies that used mutant forms of ASAP1 to 
investigate its role in vesicle trafficking and EGF uptake (Nie et al., 2006). In these 
experiments, HeLa cells were transfected with a mutant form of ASAP lacking the BAR 
domain and treated with the same fluorescein-coupled EGF that I used. Compared to 
controls transfected with the full length ASAP1, cells transfected with a mutant ASAP1 
lacking the BAR domain showed an increase in intracellular fluorescence, as 
measured by fluorescence microscopy. This is because reduced activity of ASAP1 
causes a slow down of the internalization process, resulting in an accumulation of the 
EGF-receptor complex, and therefore in an increase in the fluorescent signal (Nie et al., 
2006). In the control cells in which normal ASAP1 activity is present, the internalization 
of the receptor and clearance of the fluorescein-coupled EGF occurs more rapidly. 
Thus, the fluorescence intensity is lower. 
 
Orth and colleagues have shown a link between the formation of circular dorsal ruffles 
(CDR, or “waves”), which are one of the cytoskeletal structures ASAP1 participates in 
(Randazzo et al., 2000), and the internalization of receptors such as EGFR (Orth et al., 
2006). CDRs are formed in response to stimulation of the tyrosine kinase receptors for 
HGF, EGF and PDGF, and are found on the membrane of migratory cells. Although their 
precise function is not clear, it seems that they have a role in cell motility, as their 
appearance precedes the formation of lamellipodia (Buccione et al., 2004). These 
structures can be responsible of the sequestration and endocytosis of up to 50% of 
receptors such as EGFR (Orth et al., 2006). ASAP1 might therefore regulate the 
internalization of EGFR not only via the classical endocytotic process through its BAR 
domain, but also by contributing to this alternative pathway. 
 
5.3 ASAP1 interaction with Nm23-H1 and h-prune in EGF 
recycling 
 
The laboratory of Prof. Zollo found that h-prune and Nm23-H1, two proteins already 
known to interact with each other and to control cell motility and invasion, were able to 
co-immunoprecipitate with ASAP1. This observation led me to hypothesize that these 
three proteins might form a regulatory complex involved in the metastatic process. To 
verify whether Nm23-H1 and h-prune can indeed affect ASAP1 and its activities, I 
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investigated two functions of the ASAP1 protein, namely its role in vesicle trafficking 
and EGFR internalization, and its ability to promote motility, parameters that are highly 
relevant to metastasis formation. Loss- and gain-of-function experiments allowed me 
to investigate the influence of Nm23-H1 and h-prune on ASAP1 activity in these 
assays.  
 
I used the EGF internalization assay that I developed to investigate if and how Nm23-
H1 and h-prune affect ASAP1-dependent regulation of EGF internalization in MD MB 
231 cells. The overexpression of h-prune did not affect the internalization rate of EGF 
in the presence or absence of ASAP1. In contrast, loss- and gain-of-function 
experiments with Nm23-H1 suggested a role for Nm23H1 in EGF internalization. While 
silencing of Nm23-H1 alone had no effect on EGF internalization, the increased 
fluorescence observed after silencing ASAP1 in these assays was abrogated by the 
concomitant silencing of Nm23-H1. Ectopic expression of Nm23-H1 also resulted in a 
small but significant increase in fluorescence. However, ectopic expression of Nm23-
H1 in cells with silenced ASAP1 reduced the increase in fluorescence observed with 
ASAP1 silencing alone. Although these results do not provide any evidence that Nm23-
H1 regulates ASAP1-mediated EGF recycling, they do suggest that Nm23-H1 
participates in this process, and may serve as a “governor” that acts to maintain EGF 
internalization rates within normal boundaries. 
  
Interestingly, Nm23-H1 has been linked with the regulation of endocytosis, albeit in 
other contexts. Palacios and colleagues showed that Nm23-H1 is recruited by Arf6-
GTP to cell-cell contacts to facilitate dynamin–dependent vesicle fission (Palacios et 
al., 2002). ASAP1, an effector for Arf6, may participate in this complex, which could 
also be relevant in the internalization of EGF. Moreover, in Drosophila the homologue 
of Nm23-H1, awd, is recruited to the plasma membrane together with shi/dynamin to 
regulate the internalization of Btl/FGFR homologue, again linking Nm23-H1 with 
endocytosis (Dammai et al., 2003). Similarly it has been proposed that Nm23-H1 
could act as an unconventional GEF for dynamin, facilitating its activation, because the 
inhibition of Nm23-H1 caused a reduction in dynamin-mediated endocytosis (Krishnan 
et al., 2001). Dynamin is a large GTPase that is inactivated by hydrolyzing GTP to GDP. 
This GTPase activity is enhanced by protein interaction partners that bind to the 
proline-rich region of dynamin via SH3 domains (Hinshaw, 2000), and ASAP1 may be 
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one of these. The GTPase effector domain (GED) of dynamin is responsible for the 
GTPase activity of dynamin, but ASAP1 with its GAP domain may also contribute to the 
hydrolysis of GTP, thereby facilitating the budding of the endocytotic vesicle. This 
would mean that ASAP1 not only binds to the membrane to bend it and facilitate 
endocytosis, but may also be involved directly in dynamin–mediated vesicle fission 
(Figure 56). Moreover, it has been suggested that proteins with a BAR domain such as 
ASAP1 can destabilize the phospholipid bilayer and thereby influence the GTPase 
activity of dynamin (Ferguson and De Camilli, 2012). 
 
5.4 Effects of Nm23-H1 and h-prune on ASAP1-mediated motility 
 
A key feature of ASAP1 in promoting the metastatic process is its role in cell motility 
(Müller et al., 2010). Therefore I analysed the effects of Nm23-H1 on this activity. The 
silencing of ASAP1 in the MDA MB 231 cells resulted in a clear reduction in the motility 
of the cells, as expected. Silencing of Nm23-H1 also reduced motility to a similar 
degree, and concomitant silencing of both ASAP1 and Nm23-H1 did not lead to any 
further reduction in motility. Furthermore, ectopic expression of Nm23-H1 had no 
effect on cell motility, and also had no effect on reduced cell motility subsequent to 
ASAP1 silencing.  These findings could in principle indicate that Nm23-H1 and ASAP1 
cooperate to regulate motility, if one assumes that ASAP1 and Nm23-H1 interact 
stoichiometrically at steady state within MDA MB 231 cells. Further experiments would 
be required to investigate this possibility, for example using the wild-type and knockout 
MEFs I produced. However, it would seem unlikely that the levels of ASAP1 and Nm23-
H1 are finely balanced in this way. Thus a tentative conclusion is that Nm23-H1 affects 
motility independently of its interaction with ASAP1. The fact that the SH3 binding 
domain of ASAP1 is critically required for ASAP1-mediated motility (Müller et al., 
2010), whereas Nm23-H1 does not possess a SH3 domain and does not interfere with 
the interaction between ASAP1 and the SH3 domain-containing SLK protein provides 
further indirect support for this conclusion. 
 
On first sight it is surprising that the silencing of Nm23-H1 resulted in a decrease in 
cell motility, as Nm23-H1 is known as a metastasis suppressor, and thus its knock 
down would be expected to cause an increase in the migratory potential of the cells. 
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Other authors however have linked the expression of Nm23-H1 with tumor progression 
and poor prognosis, despite its prominent role as a metastasis suppressor (Zeng et al., 
1994; Müller et al., 1998; Xiao et al., 1998). These observations underscore the 
complex effects of Nm23-H1 in different contexts and cellular processes. 
 
I also examined the effect of h-prune on cell motility, and whether this modulates 
ASAP1-mediated cell motility. Ectopic expression of h-prune resulted in a modest but 
significant reduction in the motility of MDA MB 231 cells. This result is surprising, as 
ectopic expression of h-prune has previously been reported to promote cell motility in 
breast cancer cells (D’Angelo et al., 2004). A possible explanation for this finding is 
that the effect of h-prune on cell motility is context dependent, and that it has different 
effects in different cells. Despite modestly reducing motility, ectopic h-prune 
expression had no effect on the much greater reduction in cell motility following 
silencing of ASAP1. These data therefore do not provide any evidence that h-prune 
regulates ASAP1-mediated cell motility, but further experiments would be needed to 
substantiate this conclusion.  
 
5.5 SLK is a novel SH3 domain-containing interaction partner of 
ASAP1 that regulates cell motility independently of ASAP1 
 
Previous studies in the laboratory of Prof. Sleeman showed that the SH3 binding 
domain of ASAP1 is necessary for this protein to exert its pro-motility and pro-
metastatic effects, both in vitro and in vivo (Müller et al., 2010). The results I obtained 
with the ASAP1-knockout MEFs again confirmed the importance of the SH3 binding 
domain of ASAP1 in regulating motility. In these cells, enforced expression of wild type 
ASAP1 rescued the motility of the ASAP1 knockout MEFs, which was not the case for 
the SH3 binding domain mutant of ASAP1. 
 
To gain further insight into how ASAP1 regulates tumor cell motility and metastasis at 
the molecular level, I used a commercially-available array of proteins containing SH3 
domains to find potential new proteins that interact with ASAP1 via its SH3 binding 
domain. An interesting candidate that emerged from this screening was STE20-like 
kinase or SLK, which was then confirmed as an interaction partner for ASAP1 by 
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means of co-immunoprecipitation (Müller et al., 2010). SLK was of particular interest 
for my studies, as it has already been linked both to cell motility and to the promotion 
of tumor progression in the context of breast cancer. For example, it has been shown 
that the kinase activity of SLK is required for ErbB2-driven breast cancer cell motility 
(Roovers et al., 2009). 
 
Human SLK has been cloned and characterized from a human lung carcinoma cell line 
(Yamada et al., 2000). It is a germinal centre kinase (GCK)-related kinase that is 
ubiquitously expressed in adult tissues, and which has a role in actin stress fibre 
dissolution and the induction of apoptosis (Sabourin et al., 2000). SLK is indirectly 
associated with the microtubules and is enriched at the leading edge of migrating cells 
(Wagner et al., 2002). It is activated by the FAK/Src/MAPK pathway, and subsequently 
promotes focal adhesion turnover and cell migration (Wagner et al., 2008) (Figure 55). 
The disassembly of actin stress fibres caused by SLK is inhibited by inactive Rac1 
(Wagner et al., 2002). 	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure	   55:	   The	   role	   of	   SLK	   in	   focal	   adhesions.	   SLK	   associates	   with	   microtubules	   via	   a	   binding	  protein	  that	  remains	  to	  be	  identified	  (X).	  The	  activation	  of	  the	  integrin-­‐Src-­‐FAK	  pathways	  leads	  to	  the	  recruitment	   and	   activation	   of	   the	   microtubule-­‐SLK	   complex	   (adapted	   from	   Wagner	   and	   Sabourin	  2009). 
 
In MDA MB 231 cells, I found that ectopic expression of SLK resulted in increased cell 
motility as expected. Consistently, SLK knockdown reduced the motility of the cells, 
but to a lesser extent than ASAP1 knockdown, which may reflect the different 
 110 
efficiency of the silencing. Importantly, ectopic expression of SLK was able to rescue 
the reduction in motility caused by the knockdown of ASAP1, and restored cell motility 
to normal basal levels. The silencing of the two proteins together did not show an 
additive effect in inhibiting motility. In both the knockout and in the wild type MEFs, 
ectopic expression of SLK resulted in an increase of cell motility. Together these data 
confirm the roles of ASAP1 and SLK proteins in regulating cell motility, but suggest that 
SLK exerts its motility-promoting activities independently of ASAP1. 
 
Both ASAP1 and SLK have been described as being part of focal adhesions, and are 
involved in FAK signalling that promotes motility (Figure 56) (Wagner et al., 2008; 
Roovers et al., 2009; Brown et al., 2000; Liu et al., 2002). FAK signalling is a very 
important regulator of cell motility, and it has been linked with cancer in various 
reports (McLean et al., 2005). As SLK and ASAP1 both play a role in cell motility and 
migration, and have been implicated in tumor progression, it is tempting to speculate 
that they may share a common upstream signal, namely FAK-Src phosphorylation, but 
then independently affect different downstream pathways upon activation. This would 
reflect the redundancy of signals that is often found in cells (Kafri et al., 2009).  
 
 
Figure	  56:	  Schematic	  diagram	  showing	  the	  effects	  of	  ASAP1	  in	  the	  cell	  and	  the	  possible	  role	  of	  
its	  interaction	  partners	  in	  these	  processes.	  A.	  ASAP1	  dimerizes,	  and	  promotes	  the	  internalization	  of	  EGF.	   Nm23-­‐H1	   might	   participate	   in	   this	   process	   by	   interacting	   both	   with	   ASAP1	   and	   dynamin.	   B.	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ASAP1	   and	   SLK	   might	   be	   commonly	   activated	   by	   FAK-­‐Src	   signalling	   to	   promote	   motility.	   The	   two	  proteins	  subsequently	  act	  through	  independent	  mechanisms	  to	  regulate	  motility,	  despite	  that	  fact	  that	  they	  can	  interact	  with	  each	  other.	  	  
 
5.6 What is the relevance of the interaction of Nm23-H1 and h-
prune with ASAP1 in vivo? 
 
The cell motility and metastasis-promoting effects of ASAP1 are dependent on its SH3 
binding domain (Müller et al., 2010), as I also demonstrate here with the rescue 
experiments in the ASAP1 knockdown MEFs. Neither h-prune nor Nm23-H1 were able 
to impair the binding of ASAP1 to SLK, suggesting that h-prune and Nm23-H1 do not 
interact with ASAP1 via its SH3 binding domain (note that neither protein contains an 
SH3 domain), and also do not interfere with its ability to interact with proteins that 
contain SH3 domains. Furthermore, I did not obtain any substantial data to support 
the notion that h-prune or Nm23-H1 regulates ASAP1-mediated EGF internalization or 
cell motility. The question therefore arose as to whether the interaction between 
ASAP1 and Nm23-H1 and h-prune as evidenced by co-immunoprecipitation is relevant 
to the cell motility and metastasis promoting activity of ASAP1. To begin to address this 
issue I used size exclusion chromatography to determine the degree to which h-prune 
and Nm23-H1 are present in ASAP1-containing protein complexes extracted from MDA 
MB 231 cells. I found that Nm23-H1 and h-prune eluted in similarly-sized protein 
complexes, consistent with their reported interaction. However, little if any ASAP1 was 
present in these fractions. Furthermore, the majority of ASAP1 was found in high 
molecular weight protein complexes that eluted in fractions that contained little h-
prune or Nm23-H1. This result has several putative explanations. First, concomitant 
over expression of Nm23-H1 and h-prune may result in these two proteins 
preferentially binding to each other and excluding ASAP1 from their complex. Second, 
the strength of the interaction between ASAP1 and Nm23-H1 or h-prune to ASAP1 may 
not be enough to keep the complex intact through the chromatographic separation. As 
the lysis and buffer conditions used for the co-immunoprecipitation experiments are 
different to those required for the size exclusion chromatography, this might lead to 
contrasting results. Alternatively, the results may reflect that although ASAP1 can co-
immunoprecipate with both h-prune and Nm23-H1, these interactions represent only a 
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small minority of ASAP1 protein complexes found in MDA MB 231 cells.  Either way, 
the size exclusion chromatography results clearly show that virtually all mature ASAP1 
protein is present in high molecular weight complexes in MDA MB 231 cells, reflecting 
the multidomain nature of the protein and its ability to interact with a wide variety of 
other proteins. In further work, size exclusion chromatography will also be used to 
investigate whether SLK co-elutes with ASAP1-containing protein complexes. 
 
5.7 Conclusions 
 
In my thesis work I have substantiated the notion that ASAP1 regulates EGF 
internalization and cell motility, processes that likely underlie the ability of ASAP1 to 
promote metastasis formation. I have also confirmed that the SH3 binding domain of 
ASAP1 is important for its ability to promote cell motility, and have identified a number 
of new SH3 domain-containing proteins that interact with ASAP1, including SLK whose 
interaction with ASAP1 I could confirm using co-immunoprecipitation. Overall, my 
studies showed that three interacting partners of ASAP1, namely Nm23-H1, h-prune 
and SLK do not play fundamental roles in regulating the motility-promoting activity of 
ASAP1, and therefore probably also do not affect its ability to induce metastasis 
formation in vivo. I was also unable to find any substantial evidence to suggest that 
Nm23-H1 and h-prune modulate ASAP1-dependent EGF internalization. Together with 
the analysis of ASAP1-containing protein complexes using size exclusion 
chromatography, these data suggest that Nm23-H1 and h-prune probably do not 
contribute to any significant extent to ASAP1-dependent EGF internalization and cell 
motility. Future work will capitalize on the availability of wild type and ASAP1 knockout 
MEFs to substantiate these preliminary conclusions. Further analysis of other possible 
interaction partners, particularly those that emerged from the SH3 domain screening I 
undertook, should shed light on the proteins that regulate the motility-promoting 
activity of ASAP1 and its role in EGF internalization.  
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